IE65174B1 - BenzoÚ5,6¾Cycloheptapyridines Compositions and Methods of Use - Google Patents
BenzoÚ5,6¾Cycloheptapyridines Compositions and Methods of UseInfo
- Publication number
- IE65174B1 IE65174B1 IE291387A IE291387A IE65174B1 IE 65174 B1 IE65174 B1 IE 65174B1 IE 291387 A IE291387 A IE 291387A IE 291387 A IE291387 A IE 291387A IE 65174 B1 IE65174 B1 IE 65174B1
- Authority
- IE
- Ireland
- Prior art keywords
- compound
- cyclohepta
- benzo
- pyridine
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Cosmetics (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Derivatives of benzo[5,6]cyclohepta pyridine, and pharmaceutically acceptable salts and solvates thereof are disclosed, which possess anti-allergic and anti-inflammatory activity. Methods for preparing and using the compounds are also described.
Description
BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE The present invention relates to benzo[5,6]cyclohepta pyridines and to pharmaceutical compositions and methods of using such compounds.
United States Patents 3,326,924, 3,717,647 and 4,282,233, European published Application No. 0042544 and Villani et al., Journal of Medicinal Chemistry, Vol. 15, No. 7, pp 750-754 (1972) and Arzn. Forsch 36 1311-1314 (1986) describe certain 11-(4-piper idylidene)-511benzo[5,6]cyclohepta[1,2-b]pyridines as antihistamines. U.S. Patent 4,355,036 describes certain N-substituted piperidylidene compounds.
Furthermore, US-A-3 409 621, Journal of Med. Chem. 115 (1972), p. 750-754, EP-A-0 042 544 and EP-A-0 152 897 discloses aza isosteres of ,ll-dihydro-5H-dibenzocycloheptene compounds having antiallergic and anti histaminic properties.
Therefore the problem underlaying the present invention is the provision of compounds having a higher pharmaceutical activity.
The invention in its chemical compound aspect is a compound having the structural formula I: -2or a pharmaceutically acceptable salt or solvate thereof, wherein: one of a, b, c and d represents N or NR° where R° is 0", -CHj or -(CH2)nCO2H where n is 1 to 3, and the remaining a, b, c and d groups are CH, which remaining a, b, c and d groups optionally may be substituted with R1 or R2; 2 R and R may be the same or different and each independently represents halo, -CF-j, -OR10, -COR10, -SR10, -N(R10)2r -NO2, -OC(O)R10, -CO2R10, -OCOjR11, alkynyl, alkenyl or alkyl, which alkyl or alkenyl group may be substituted with halo, -OR10 or -CC^R10; R2 and R^ may be the same or different and each independently represents H, any of the substituents of R1 and R2, or R2 and R^ together may represent a saturated or unsaturated C^-C-j fused ring; R , R , R and R each independently represent H, -CFp alkyl or aryl, with all available substitutable carbon atoms of the carbocylic group being intended as possible points of attachment, which alkyl or aryl may be substituted with -OR^, -SR^, -N(R1^)2< -NO^, COR^°, OCOR10, OCOjR11, CO2R10, OPO3R10 or one of R5, R6, R7 and R° may be taken in combination with R as defined below to represent -(CH2)r- where r is 1 to 4 which may be substituted with lower alkyl, lower alkoxy, -CF3 or aryl; R10 represents H, alkyl or aryl; R11 represents alkyl or aryl; X represents N or C, which C may contain an optional double bond to carbon atom 11; the dotted line between carbon atoms 5 and 6 represents an optional double bond, such that when a double bond is present, A and B independently represent H, -R10, -OrU or -OC(O)R10, and when no double bond is present between carbon atoms 5 and 6, A and B each independently represent H2/ -(OR10)alkyl and H, (alkyl)2/ -H and -OC(O)R10r H and -OR10, =0· aryl and H, =N0r1° or -O-(CH2)p-O- where p is 2, 3 or 4 and R10 is as previously defined; -3Z represents 0 or S such that (a) when Z is O, R may be taken in combination • 5 6 7 ft with R , R, R' or R° as defined above, or represents H, aryl, alkyl, cycloalkyl - representing saturated carbocyclic rings branched or unbranched of from 3 to 20 carbon atoms, alkenyl, alkynyl or -D wherein -D represents heterocycloalkyl, previously defined and W is O, S or NR1® wherein R1® is as defined above, said cycloalkyl, alkyl, alkenyl and alkynyl being optionally substituted with from 1-3 groups selected from halo, -CON(R10)2, aryl, -OR12, -SR12, -N(R10)2, -N(R10)CO2R10, -COR12, -NO2 or D, wherein -D and R1® are as defined above and R12 represents R1®, -(CH2)mOR1® or -(CH2)gC02R1® wherein R1® is as previously defined, m is 1 to 4 and q is 0 to 4, said alkenyl and alkynyl R groups not containing -OH, -SH or -N(R1®)2 on a carbon containing a double or triple bond respectively; and (b) when Z represents S, R represents in addition to those R groups above, aryloxy or alkoxy; said alkyl - (including the alkyl portions of alkoxy, alkylamino and dialkylamino) - representing straight and branched carbon chains and contains from one to twenty carbon atoms, said alkenyl - representing straight and branched carbon chains having at least one carbon to carbon double bond and containing from 2 to 12 carbon atoms, said alkynyl - representing straight and branched carbon chains having at least one carbon to carbon triple bond and containing from 2 to 12 carbon atoms, and -4said aryl - (including the aryl portion of aryloxy) - representing a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring.
In a preferred embodiment of the invention, Z represents 0 or S, and R represents alkyl, cycloalkyl, alkenyl, aryl or alkyl substituted with -OR1-2, -SR , -N(R1°)2or -COR12· More Preferably, when Z represents 0 or S, R represents alkyl having from 1 to 3 carbon atoms, or alkyl of from 1 to 3 carbon atoms substituted with -OR12, -SR12, -N(R1®)2, or COR12. Preferably one or both of R2 and R^ is halo, e.g. chloro or fluoro. The most preferred value of R2 and/or R^ is a halogen located at carbon atom 8 and/or 9, as sh^wn in the following numbered ring structure: The nitrogen preferably is located at position a. R5, £ 7 Q R , R , R , A and B preferably are Η. X preferably is a single or double bonded carbon. The bond between positions 5 and 6 preferably is a single bond. The bond between the piperidyl ring and the cycloheptyl ring preferably is a double bond.
Compounds of the invention include: 11- (l-acetyl-4-piper idylidene) -6,11-dihydro-5_Hbenzo[5,6]cyclohepta[1,2-b]pyridine; 11-(l-methoxyacetyl-4-piperidylidene)-6,11-dihydro5ji-benzo [ 5,6] cyclohepta (1,2-b] pyr idine ; 11-(l-benzoyl-4-piperidylidene)-6,ll-dihydro-5Hbenzo[5,6]cyclohepta[1,2-b]pyridine; - 5 11-(1-(3-chlorophenylacetyl)-4-piperidylidene]-6,11dihydro-5jl-benzo [5,6] cyclohepta [1,2-b] pyr idine; 11-(1-(3,4-dimethoxybenzoyl)-4-piper idylidene]-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyr idine; 8-chloro-ll-(l-acetyl-4-piperidylidene)-6,11-dihydro5H-benzo[5,6]cyclohepta[1,2-b]pyr idine; 8-chloro-ll-(l-propionyl-4-piper idylidene)-6,11dihydro-5II-benzo [5,6] cyclohepta [ 1,2-b] pyr idine; 8-chloro-ll-(1-trimethylacetyl-4-piperidylidene)6, ll-dihydro-5JH-benzo [5,6] cyclohepta [ 1,2-b] pyr idine; 8-chloro-ll-[1-(t-butylacetyl)-4-piperidylidene]6.11- dihydro-5H-benzo[5,6]cyclohepta FI,2-b]pyr idine; 8-chloro-ll-(l-methoxyacetyl-4-piper idylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-chloro-ll-[1-(ethoxyacetyl)-4-piperidylidene]-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyr idine; 8- chloro-ll-[1-(2-hydroxypropionyl)-4piper idylidene]-6,ll-dihydro-5Hbenzo[5,6]cyclohepta[l,2-b]pyridine? 9- chloro-ll-(l-methoxyacetyl-4-piper idylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-chloro-ll-[1-(2-methoxypropionyl)-4piper idylidene] -6,ll-dihydro-5ll-benzo[ 5,6] cyclohepta[1,2-b]pyridine; 8-chloro-ll-[1-(2-oxopropionyl)-4-piper idylidene]6.11- dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine; -68-chloro-ll-[l-(1-ethoxycarbonylmethyl)-4piperidylidene] 6,ll-dihydro-5ji-benzo[5,6]cycloheptaI1,2-b]pyridine; 8-chloro-ll-[1-(t-butoxycarbonylaminoacety1)-4piperidylidene]-6,ll-dihydro-5Hbenzo[5,6]cyclohepta[1,2-b]pyr idine; 8-chloro-ll-(1-trifluoroacetyl-4-piperidylidene)6,ll-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-chloro-ll-(l-benzoyl-4-piperidylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyr idine; 8-chloro-ll-[1-(3,4,5-trimethoxybenzoyl)-4piper idylidene]-6,ll-dihydro-5Hbenzo[5,6]cyclohepta[1,2-b]pyridine; 8-fluoro-ll-(l-acetyl-4-piperidylidene)-6,11-dihydro5il-benzo [5,6] cyclohepta [ 1,2-b] pyridine; 8-fluoro-ll-(l-n-butyryl-4-piper idylidene)-6,11dihydro-5_H-benzo [ 5,6] cyclohepta [ 1,2-b] pyr idine; 8- fluoro-11-(1-methoxyacetyl-4-piper idylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 9- fluoro-11-(l-acetyl-4-piperidylidene)-6,11-dihydro5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 9-fluoro-ll-(1-methoxyacetyl-4-piper idylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; -78.9- difluoro-11-(l-methoxyacetyl-4-piperidylidene)6, ll-dihydro-511-benzo [5,6] cyclohepta [ 1,2-b] pyr idine; 8-methyl-ll-(l-methoxyacetyl-4-piperidylidene)-6,11dihydro- 5H-benzo [5,6]cyclohepta[1,2-b]pyridine; 8-chloro-ll-(l-cyclopropylcarbonyl-4-piperidylidene) 6, ll-dihydro-5II-benzo [5,6] cyclohepta [ 1,2-b] pyr idine; 8-chloro-ll-(1-n-butyryl-4-piperidylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyr idine; 8- methoxy-ll-(l-acetyl-4-piper idylidene)-6,11dihydro-5H^-benzo [5,6]cyclohepta[1,2-b]pyridine; 9- chloro-ll-(l-acetyl-4-piperidylidene)-6,11-dihydro 5_H-benzo [5,6] cyclohepta [ 1,2-b] pyr idine; 8.9- difluoro-11-(l-acetyl-4-piper idylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-methyl-ll-(l-acetyl-4-piperidylidene)-6,11-dihydro SH^benzo[5,6]cyclohepta[1,2-b]pyr idine; 8.9- dichloro-ll-(l-acetyl-4-piperidylidene)-6,11dihydro- 5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-chloro-ll-[1-(2-(2-hydroxyethoxy) ethyl)-4piper idylidene] -6, ll-dihydro-5_H-benzo [ 5,6] cyclohepta [1,2-b]pyridine; 8-chloro-ll-[1-[4-(4-t-butylphenyl)-4-hydroxybutyl]4-piper idylidene] - 6, ll-dihydro-5_H-benzo [5,6] cyclohepta[1,2-b]pyridine; -88-chloro-ll-(l-ethoxydicarbonyl-4-piper idylidene)6, ll-dihydro-5II-benzo [ 5,6]cyclohepta[1,2-b] pyridine 8-chloro-ll-(l-aminoacetyl-4-piper idylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyr idine 8-chloro-ll-(1— formyl-4-piperidylidene)-6,11-dihydro5H-benzo[5,6]cyclohepta[1,2-b]pyr idine; 8-chloro-ll-(l-thiobenzoyl-4-piper idylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyr idine; 8-chloro-ll-[l-thioethoxycarbonyl-4-piperidylidene]6,ll-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-ll-[l-thioacetyl-4-piper idylidene]-6,11dihydro-511-benzo [5,6] cyclohepta [ 1,2-b] pyr idine; 8-Bromo-ll-[1-acetyl-4-piper idylidene]-6,11-dihydro5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-ll-(l-acetyl-4-piper idylidene)-6,11-dihydro5ji-benzo [ 5,6] cyclohepta [ 1,2-b] pyr idine N-oxide; 8-Chloro-ll-(1-acetyl-4-piperidylidene)-llH-benzo[5,6]cyclohepta[1,2-b]pyr idine; 8-Chloro-ll-(l-acetyl-4-piperazinyl)-6,ll-dihydro-5Hbenzo[5,6]cyclohepta[1,2-b]pyr idine; 8-Chloro-ll-(l-methylaminocarbonyl-4-piperidylidene)6 , ll-dihydro-5II-benzo [5,6] cyclohepta [ 1,2-b] pyridine; 13-(1-acetyl-4-piper idylidene)6,13-dihydro-5Hnaphtho[2',3’:5,6]cyclohepta[1,2-b]pyridine; -98-Chloro-ll-[l-acryloyl-4-piperidylidene]-6,11dihydro-5JH_-benzo (5,6] cyclohepta (1,2-b]pyridine ; 8-Chloro-ll-(1-(2-methoxy-2-methylpropionyl)-4piperidylidene] -6, ll-dihydro-S^T-benzo [5,6] — cyclohepta[1,2-b]pyridine; l-Methyl-8-chloro-ll-(l-acetyl-4-piperidylidene)6, ll-dihydro-5j£-benzo [5,6] cyclohepta [1,2-b]pyridinium iodide; 8-Chloro-ll-(1-acety1-4-piperidinyl]-11Hbenzo(5,6]cyclohepta[1,2-b]pyridine; -Hydroxy-8-chloro-l1-(1-acety1-4-piperidylidene)6,1 l-dihydro-5H_-benzo [5,6]cyclohepta [1,2-b]pyridine ; 8-Chloro-ll-(l-dichloroacetyl-4-piperidylidene]-6,11dihydro-5jl_-benzo (5,6] cyclohepta [1,2-b] pyridine; -Methyl-8-chloro-ll-[1-acety1-4-piperidylidene]-5jl·benzo[5,6]cyclohepta(1,2-b]pyridine; 3-Methyl-8-chloro-ll- (l-acetyl-4-piperidylidene ] -5_H_benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-ll-[1-acety1-4-piperidylidene]-6,11-dihydro5H_-benzo [5,6] cyclohepta [1,2-b]pyridin-5-one ; -Methyl-8-chloro-(1-acety1-4-piperazinyl)-6,11dihydro-5J£-benzo [5,6] cyclohepta [1,2-b] pyridine ; 8-Chloro-ll-[1-acety1-2-methy1-4-piperazinyl]-6,lldihydro-5H_-benzo [5,6] cyclohepta [1,2-b] pyr idine -108-Chloro-ll-[l-acetyl-(E)-2,6-dimethyl-4piperidylidene ] -6, ll-dihydro-5H_-benzo [5,6] cyclohepta [ 1,2-b]pyridene; 8-Chloro-ll-[l-acetyl-(Z)-2,6-dimethy1-4piperidylidene ] -6, ll-dihydro-5j^-benzo (5,6] cyclohepta(1,2-b]pyridine; 8-Chloro-ll-[l-acetyl-2,6-dimethy1-4-piperazinyl]6, ll-dihydro-5j£-benzo [5,6] cyclohepta [1,2-b]pyridine ; 8-Chloro-ll-(1-methoxyacetyl-4-piperazinyl)-6,11dihydro-Sjr-benzo (5,6] cyclohepta [1,2-b]pyridine ; 8,9-difluoro-11-(l-acetyl-4-piperidylidene)-6,11dihydro-5_H_-benzo (5,6] cyclohepta (1,2-b]pyridine-Noxide; 8-Chloro-ll-(l-formyl-4-piperazinyl )-6,11-dihydro-5Jbbenzo(5,6]cyclohepta[1,2-b]pyridine; 11-( l-Acetyl-4-piperidylidene )-6 , ll-dihydro-5jl_benzo(5,6]cyclohepta[1,2-c]pyridine; 2- (8-Chloro-5,6-dihydro-llj£-benzo (5,6] cyclohepta [1,2b]pyridin-ll-yl]hexahydropyrrolo [1,2-a]pyrazin-6( 2H_)one; 11- [1-(aminocarbonyl)-4-piperidylidene-6,11-dihydro5H_-benzo [5,6] cyclohepta [1,2-c]pyridine; and 3,8-dichloro-ll-(1-acety1-4-piperidylidene)-6,11dihydro-5Fl_-benzo [5,6] cyclohepta [1,2-b]pyridine . -11Particularly preferred compounds include: 8-Chloro-ll-(l-acetyl-4-piper idylidene)-6,11-dihydro5jl-benzo [5,6] cyclohepta [ 1,2-b] pyr idine; 8-Chloro-ll-(l-methoxyacetyl-4-piperidylidene)-6,11dihydro- 5^-benzo [ 5,6] cyclohepta [1, 2-b] pyr idine; 8-Chloro-11-(l-propionyl-4-piperidylidene)-6,11dihydro- 5^-benzo[ 5,6] cyclohepta [1,2-b] pyr idine; 8- Fluoro-ll-(l-acetyl-4-piperidylidene)-6,11-dihydro· 5^-benzo[5,6]cyclohepta[1,2-b]pyr idine; 9- Fluoro-ll-(l-acetyl-4-piperidylidene)-6,11-dihydro· 5H-benzo[5,6]cyclohepta[1,2-b]pyr idine; 8-Bromo-ll-[l-acetyl-4-piperidylidene]-6,11-dihydro5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8,9-Difluoro-ll-(l-acetyl-4-piperidylidene)-6,11dihydro- 5H-benzo[5,6]cyclohepta[1,2-b]pyr idine; 11- (l-Acetyl-4-piperidyl) -6, ll-dihydro-5IIbenzo[5,6]cyclohepta[1,2-b]pyridine; 3,8-Dichloro-11-(l-acetyl-4-piperidylidene)-6,lldihydro-5_H-benzo[5,6] cyclohepta[1, 2-b]pyridine; 8-Chloro-ll-(l-acetyl-4-piperazinyl)-6,11-dihydro-5H benzo[5,6]cyclohepta[1,2-b]pyridine; and 8-Chloro-ll-(l-acetyl-4-piperidinyl)-6,ll-dihydro-5H benzo[5,6]cyclohepta[1,2-b]pyridine N-oxide. -12The invention also is directed at a process for producing a compound having structural formula I wherein the substituents are as previously defined by: a) reacting a compound of formula II with a compound of formula III, wherein L represents a suitable Z II R—C—L III b) di formula V with rect conversion of an N-alkyl compound o a compound of formula III Z + X u R-C-L III V -13or, c) cyclization of a compound of formula XII B / R R U XII The invention also is directed at a compound of the formula XII A B U XII wherein the substituents have the same definitions as in formula I.
The invention also involves a composition which comprises a compound of formula I as defined above in combination with a pharmaceutically acceptable carrier.
The compounds of Formula I of the present invention are effective in treating allergy or inflammation in a mammal when administered to said mammal in an amount effective to treat allergy or inflammation, respectively. -14The invention also comprises a method for making a pharmaceutical composition comprising mixing a compound of formula I with a pharmaceutically acceptable carrier.
As used herein, the following terms are used as defined below unless otherwise indicated: alkyl - (including the alkyl portions of alkoxy, alkylamino and dialkylamino) - represents straight and branched carbon chains and contains from one to twenty carbon atoms, preferably one to six carbon atoms; alkanediyl - represents a divalent, straight or branched hydrocarbon chain having from 1 to 20 carbon atoms, preferably 1 to 6 carbon atoms, the two available bonds being from the same or different carbon atoms thereof, e.g., methylene, ethylene, ethylidene, -CH2CH2CH2-, -CH2CHCH3, -^HCH2CH3, etc. cycloalkyl - represents saturated carbocyclic rings branched or unbranched of from 3 to 20 carbon atoms, preferably 3 to 7 carbon atoms; heterocycloalkyl - represents a saturated, branched or unbranched carbocylic ring containing from 3 to 15 carbon atoms, preferably from 4 to 6 carbon atoms, which carbocyclic ring is interrupted by 1 to 3 hetero groups selected from -0-, -S- or -NR1 (suitable heterocycloalkyl groups including 2- or 3tetrahydrofuranyl, 2- or 3-tetrahydrothienyl, 2-, 3or 4-piperidinyl, 2- or 3-pyrrolidinyl, 2- or 3piperizinyl, 2- or 4-dioxanyl, etc.); -15alkenyl - represents straight and branched carbon chains having at least one carbon to carbon double bond and containing from 2 to 12 carbon atoms, preferably from 3 to 6 carbon atoms; alkynyl - represents straight and branched carbon chains having at least one carbon to carbon triple bond and containing from 2 to 12 carbon atoms, preferably from 2 to 6 carbon atoms; aryl (including the aryl portion of aryloxy) represents a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g., aryl is a phenyl ring), with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted with one or more of halo, alkyl, hydroxy, alkoxy, phenoxy, CF3, amino, alkylamino, dialkylamino, -COOR1® or -NO2; an<^ halo - represents fluoro, chloro, bromo and iodo.
Certain compounds of the invention may exist in 25 different isomeric as well as conformational forms. The invention contemplates all such isomers both in pure form and in admixture, including racemic mixtures.
The compounds of the invention of formula I can exist in unsolvated as well as solvated forms, including hydrated forms, e.g., hemihydrate. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol and the like are equivalent to the unsolvated forms for purposes of the invention. -16As noted above, the benzene ring structures of formula I may contain one or more substituents R1, R2, R3 and R4. Similarly, the heterocyclic ring D may contain one or more of R2 and R4. In compounds where there is more than one such substituent, they may be the same or different. Thus compounds having combinations of such substituents are within the scope of the invention. Also, the lines drawn into the rings from the r3and R4 groups indicate that such groups may be attached at any of the available positions. For example, 3 4 the R and R groups may be attached at any of the 7, 8, 9 or 10 positions.
Certain compounds of the invention will be acidic in nature, e.g. those compounds which possess a carboxyl or phenolic hydroxyl group. These compounds may form pharmaceutically acceptable salts. Examples of such salts may include sodium, potassium, calcium, aluminum, gold and silver salts. Also contemplated are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, Nmethylglucamine and the like.
Certain basic compounds of the invention also form pharmaceutically acceptable salts, e.g., acid addition salts and .quaternary ammonium salts. For example, the pyrido- or pyrazino- nitrogen atoms may form salts with strong acid, while compounds having basic substituents such as amino groups also form salts with weaker acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those in the art. The salts are prepared by contacting the free base form with -17a sufficient amount of the desired acid to produce a salt in the conventional manner. The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium hydroxide, potassium carbonate, ammonia and sodium bicarbonate. The quaternary ammonium salts are prepared by conventional methods, e.g., by reaction of a tertiary amino group in a compound of formula I with a quaternizing compound such as an alkyl iodide, etc. The free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the salts are otherwise equivalent to their respective free base forms for purposes of the invention.
All such acid, base and quaternary salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention. 2q The following processes may be employed to produce compounds of general structural formula I.
A. A compound of general formula II may be reacted with compound III in the presence of base to produce compounds of general structural formula I. > I III II -18Representative examples of appropriate bases are pyridine and triethylamine. L designates a suitable leaving group. For example, if Z is 0 or S, a compound of compound III may be an acyl halide (e.g., L = halo) or 5 ί acyl anhydride, (e.g., L is -O-C-R). Alternatively, if the leaving group is hydroxy a coupling reagent may be employed to form Compound I. Examples of coupling agents • include N,Ν’-dicyclohexylcarbodiimide (DCC) and N,N'10 carbonyldiimidazole (CDI). The leaving group may also be alkoxy, in which case the compounds of formula I may be produced by refluxing a compound of formula II with an excess of a compound of formula III.
If compound III is a compound R-C^-L, L can be 15 any easily displaced group, such as halo, p-toluene sulfonyloxy, methyl sulfonyloxy, trifluoromethylsulfonyloxy and the like.
Compounds of general formula II may be prepared by cleaving the group COORa from the corresponding 2Q carbamates IV, for example, via acid hydrolysis (e.g., HCl) or base hydrolysis (e.g., KOH): wherein Ra is a group which does not prevent the cleavage reaction, e.g., Ra is an optionally substituted alkyl such as ethyl. -19Alternatively, depending upon the nature of Ra, as determined by one skilled in the art, Compound IV may be treated with an organometallic reagent (e.g., CH3L1), a reductive reagent (e.g., Zn in acid), etc., to form compounds of formula II.
Compound TV-may be prepared from the N-alkyl compound shown as formula V below, in the manner -=>· IV It also will be apparent to one skilled in the art that there are other methods for converting Compound V to Compound II. For example, treatment of Compound V with BrCN via von Braun reaction conditions would provide nitrile IVa. Subsequent hydrolysis of the nitrile under either aqueous basic or acidic conditions would produce Compound II. This method is preferable when there is substitution on the piperidine or piperazine ring.
IVa -20B. The compounds of formula I where Z is O or S may be made by an alternative process using direct conversion of the N-alkyl compound V with an appropriate compound of formula III such as an acyl halide or acyl anhydride. Preferably the reaction is run in the presence of an appropriate nucleophile (e.g. Lil, etc.) and solvent (e.g., toluene, dioxane or xylenes). An appropriate base, may be added, and heating may be required. Typically, a temperature ranging from 50-150°C (preferably 100-120°C) is utilized.
V Compound V is prepared as described in part A above.
PREPARATION OF DOUBLE BOND COMPOUNDS Compounds of the formula la, where X is a carbon atom having a double bond to carbon 11, may be prepared from compound Va as described above. Compounds of formula Va may be produced by the methods disclosed generally in U.S. Patent 3,326,924 or alternatively may be prepared by a ring closure reaction, wherein the desired cycloheptene ring is formed by treating compound VI with a super acid. Suitable super acids for this purpose include, for example, HF/BF-j, CF3SO3H (triflic acid), CH3SO3H/BF3, etc. The reaction can be performed in the absence of, or with, an inert co-solvent such as -21CH2Cl2· The temperature and time of the reaction vary with the acid employed. For example, with HF/BF3 as the super acid system the temperature may be controlled so as to minimize side reactions, such as HF addition to the exocyclic double bond. For this purpose, the temperature is generally in the range of from about +5°C to -50°C. With CF^SC^H as the super acid system, the reaction may be run at elevated temperatures, e.g., from about 25°C to about 150°C and at lower temperatures but the reaction then takes longer to complete.
Generally the super acid is employed in excess, preferably in amounts of from about 1.5 to about 30 acid alkyl VI A ketone compound of formula VI may be formed by hydrolysis of VII e.g., such as by reacting a Grignard intermediate of formula VII with an aqueous acid (e.g., aqueous HCl). Ia in formula VII represents chloro, bromo or iodo. -22The Grignard intermediate VII is formed by the reaction of the cyano compound VIII with an appropriate Grignard reagent IX prepared from l-alkyl-4halopiperidine. The reaction is generally performed in an inert solvent, such as ether, toluene, or tetrahydrofuran, under general Grignard conditions e.g., temperature of from about 0°C to about 75°C. Alternatively, other organometallic derivatives of the 1alkyl-4-halo piperidine can be employed.
VIII IX VII The cyano compound of formula VIII is produced by converting the tertiary butyl amide of formula X with a suitable dehydrating agent, such as POCI3, SOC12/ P2°5' toluene sulfonyl chloride in pyridine, oxalyl chloride in pyridine, etc. This reaction can be performed in the absence of or with a co-solvent, such as xylene.
The dehydrating agent such as POCI3 is employed in equivalent amounts or greater and preferably in amounts of from about 2 to about 15 equivalents. Any suitable temperature and time can be employed for performing the reaction, but generally heat is added to accelerate the reaction. Preferably the reaction is performed at or near reflux.
VIII The tert-butylamide of formula X may be produced by reaction of a compound of formula XIa and Xlb, in the presence of base, where G is chloro, bromo or iodo.
The compound of formula XI may be formed by hydrolysis of the corresponding nitrile wherein the appropriate cyano-methyl pyridine, such as 2-cyano-3methylpyridine, is reacted with a tertiary butyl compound in acid, such as concentrated sulfuric acid or concentrated sulfuric acid in glacial acetic acid. Suitable tertiary butyl compounds include, but are not limited to, t-butyl alcohol, t-butyl chloride, t-butyl bromide, t-butyl iodide, isobutylene or any other compound which under hydrolytic conditions forms t-butyl carboxamides with cyano compounds. The temperature of the reaction will vary depending upon the reactants, but generally the reaction is conducted in the range of from about 50eC to about 100°C with t-butyl alcohol. The reaction may be performed with inert solvents, but is usually run neat. -24An alternative process for the formation of compounds having general structural formula la involves direct cyclization of the Compound XII as shown below.
Cyclization to form the cycloheptene ring is accomplished with a strong acid (e.g., triflic, polyphosphor ic, HF/BF-j), and may be performed in an inert solvent, such as ether, toluene or THF. The temperature and time may vary with the acid employed, as described in process A above.
Compounds of formula XII where Z = 0 or S may be prepared by treating a compound of formula VI with an appropriate acyl halide or acyl anhydride of formula III. Most preferably this reaction is run in the presence of a good nucleophile, such as Lil, in the appropriate solvent, such as toluene, dioxane or xylene, and at a temperature ranging from 50-150°C, preferably 100-120°C.
XII V I -25A second method of preparing compounds of formula XII involves reacting an unsubstituted piperidylidene compound of formula XIV with the appropriate acyl halide or acyl anhydride of formula III in the presence of base, such as pyridine or triethylamine. Alternatively, if L = OH in compound III, then coupling of compound XIV with compound III may require use of a conventional coupling reagent, such as DCC or CDI. If compound III is of the formula RCH2L, compounds of formula I where Z = H2 will be produced. In such case, the leaving group can be any easily displaced group, such as halo, p-toluene sulfonyloxy, methyl sulfonyloxy, trifiuoromethyl sulfonyloxy, etc.
Compounds of formula XIV are produced from the corresponding carbamates of formula XV, via acid hydrolysis, using for example, aqueous hydrochloric acid, or base hydrolysis using for example, potassium hydroxide. Alternatively, some compounds can be prepared by treating the carbamate, formula XV, with an organometallic reagent, such as methyl lithium or a reductive reagent, such as zinc in acid, etc., depending upon the nature of the Ra group. For example, if Ra is a simple alkyl group, CO2Ra may be cleaved by alkaline hydrolysis at 100°C.
The carbamate compounds of formula XV may be prepared from the appropriate alkyl compound of formula VI by treatment with a chloroformate, preferably in an inert solvent, such as toluene, with warming to approximately 80°C. Other alternative methods are available for the conversion of XIII to XII as previously described (e.g. Von Braun reaction conditions).
Compounds of formula VI may be prepared as described in process A above! PREPARATION OF PIPERAZINE ANALOGS Compounds of the piperazine type lb, where X is N in formula I, are best prepared via alkylation of the appropriately substituted piperazine Compound XVI with Compound XVII containing the appropriately substituted halide (such as Cl, Br, I) or other similar leaving group (tosyloxy or mesyloxy). The reaction usually is conducted in an inert solvent such as THF or toluene, -27optionally with a base such as triethylamine or potassium carbonate, typically at a temperature range of ambient to reflux to produce Compound XVIII.
XVI XVII XVIII In this reaction Rc is H, CO2Ra, C(Z)R or alkyl. The preparation of compound XVII where L is Cl is analogous to the procedure described in U.S. Patent No. 3,409,621. One skilled in the art can prepare other derivatives of XVII (e.g. L is Br, I, mesyloxy, tosyloxy). When Rc is C(Z)R these are compounds of the invention. When Rc is H, alkyl or CO2Ra, these are converted to compounds of the invention by processes previously described herein.
An alternative route for generating Compound XVIII is by reductive amination of the aza ketone XIX with the appropriately substituted piperazine XVI.
XVI XIX XVIII -28The reaction typically is carried out in a polar solvent, such as methanol or ethanol optionally in the presence of a dehydrating agent such as 3A molecular sieves. The intermediate Schiff base can be reduced to Compound XVIII by employing a variety of reducing agents such as NaCNBHj or catalytic hydrogenation, for example, hydrogen over Pd/C.
When Rc is C(Z)R, these are the compounds of the present invention. When Rc is H, CC^R3 or alkyl, these are converted to compounds of the invention as previously described.
PREPARATION OF SINGLE BOND COMPOUNDS Compounds of the formula Ic, where X is a carbon atom having a single bond to carbon atom 11, may be prepared by the following methods.
A. Compounds of formula VI may be converted to the corresponding alcohol Compound XX by employing an appropriate reducing agent. The reduction can be accomplished with a variety of reducing agents (e.g.
NaBH^ or LiAlH^) in an inert solvent such as THF or ether.
VI XX Compound XX may be cyclized to Compound XXI via a variety of methods. For example, the cyclization may be conducted under conditions similar to those described for -29the cyclization of compound VI to compound V using, for example, PPA or tri flic acid. 2ΖΓ to compounds of the described methods.
XX The alkyl then may be converted present invention by previously B. Alternatively, compounds of the invention can be prepared from XII by methods similar to those described above to reduce compound XII to compound XXII and to cyclize compound XXII to compound Ic.
XII XXII In formula XXIII the double bond can be catalytically hyrogenated to Compound XXIV by a variety of catalysts, such as Pt, Rh, Ru or Pd on various supports as described in U.S. Patent Nos. 3,419,565; 3,326,924; and 3,357,986.
Alternatively, the double bond can be isomerized to the bridgehead using a superacid, such as triflic acid at high temperature (e.g. 150-200°C) to produce Compound XXV. Subsequent catalytic hydrogenation preferably using Rh or Ru will then provide Compound XXIV.
XXV XXIV When Rc is C(Z)R the compounds of formula XXIV are compounds of the present invention. When Rc is H, alkyl or CO2^af the compounds are converted to compounds of the present invention as previously described.
C. A third method for the preparation of the subject compounds is by the use of the appropriately substituted Grignard reagent XXVI (or other corresponding metalated reagent M e.g., organolithium, etc.). Compound XXVI can be reacted with compound XVII where L is a leaving group (e.g. chloride) to provide the desired Compound XXI.
XVII XXVI XXI These reactions generally are conducted in an inert solvent such as ether, toluene, or THF at a temperature range of about -78 to about +50°C.
Alternatively, the metalating substituent and the leaving substituent could be interchanged and reacted under the same conditions to XXI.
Compound XXI can be converted to compounds of the invention as previously described. Further details on these processes are described in U.S. Patent Nos. 3,419,565; 3,326,924; 3,357,986 and in Org. Chem. 50 p. 339 (1985).
D. Alternatively, compounds of formulae XXVI and XXVII, the preparation of which is disclosed in U.S. Patent Nos. 3,419,565; 3,326,924; and 3,357,986, can be used to provide Compound XXI. This can be accomplished by reductive removal of the alcohol under a variety of conditions e.g. the methods disclosed in J.A.C.S. 104 p. 4976 (1982) and in J. Org. Chem. 50 p. 339 (1985).
XXVI XXVII XXI Compound XXI may be converted to compounds of the present invention as previously described.
SUBSTITUTION OF THE BRIDGEHEAD The following process may be employed to produce compounds of structural formula I substituted at one or more of the bridgehead carbon atoms. For the compounds XXX through XXXIII which are substituted at one bridgehead carbon atom, the substitution group shown may have a bond drawn into the cycloheptane ring through the bridgehead, "rather than to a specific bridgehead carbon atom. This is used to indicate that attachment of the substitution group to a particular bridgehead carbon atom is a function of the starting compound. For example, if the methoxy group of compound XXXI below is attached to bridgehead carbon 5, the carbonyl group on the bridgehead of compound XXXIII will be positioned at carbon 5 also. However, both isomers substituted at positions 5 and/or 6 are contemplated as being within the scope of the invention.
By substituting an isomer of the precursor compound, a compound can be synthesized having the substitution on the bridgehead carbon atoms different from that disclosed in the drawing.
XXVIII XXIX The bridgehead of Compound XXVIII, which is disclosed in U.S. Patent 3,326,924, is first brominated with an appropriate brominating agent, such as Nbromosuccinimide (NBS) in the presence of an initiator, such as azobisisobutyryl nitrile (ABIN), benzoyl peroxide or the like in an inert solvent, such as CCl^, benzene or a similar solvent. Heat or light may be required to Ί0 initiate the reaction. The bromine on the bridgehead may then be eliminated with base to form the olefinic Compound XXIX. Examples of suitable bases for elimination include diazabicycloundecane (DBU), diazabicyclononane (DBN) and diazabicyclooctane (DABCO). Elimination is typically performed in an inert solvent at reflux temperature. Examples of suitable inert solvents include CH2CI2» CCI4, toluene, tetrahydrofuran (THF) , dioxane, and CHCl-j, with CHCI3 being preferred. 2Q Alternatively, Compound XXVIII may be refluxed in the presence of an oxidizing agent to yield compound XXIX. Representative examples of oxidizing agents suitable for oxidizing Compound XXVIII include 2,3dichloro-5,6-dicyano-l,4-quinone (DDQ) and SeO2· XXIX XXX Compound XXIX may be converted to Compound XXX by adding excess powdered AgNO3 in methanol, followed by the addition of excess Br2, which bromoether ificates the unsubstituted bridgehead carbon atom. The bridgehead bromine is then eliminated with excess base, such as DBU to provide a compound of formula XXX. The reaction may be run in an inert solvent such as CHC13 at reflux temperature. The resultant isomeric mixture may be separated by column chromatography or any other appropriate method.
A compound of formula XXXI is prepared by treating the 5-substituted or 6-substituted isomer represented by compound XXX with a Grignard reagent XXVI or similar metalated reagent in an inert solvent, such as ether, benzene, or tetrahydrofuran (THF). Compound XXVI is prepared in a known manner from magnesium and the 4chloro N-substituted piperidine. The reaction may be -35refluxed if necessary, after which it may be quenched with NH^Cl to form compound XXXI.
XXXI XXXII XXXIII A compound of formula XXXI may be hydrolyzed with any strong, aqueous acid, for example, 80-95% H2SO4 or HCl, having a pH less than 1, at a temperature not higher than room temperature for not generally longer than one hour to produce an intermediate compound of formula XXXII.
After complete hydrolysis, compound XXXII may be dehydrated with CF3SO3H (triflic acid) or a similar acid to yield compound XXXIII. Examples of other acids for dehydrating compound XXXII at carbon atom 11 include, for example, HF/BF3, CH3SO3H/BF3, etc. The reaction can be performed in the absence of or with an inert cosolvent such as CH2CI2. The temperature and time of the reaction vary with the acid employed. When triflic acid is used as the super acid system, the temperature may be controlled to minimize side reactions. For example, Compound XXXII having a carbonyl at carbon atom 5 is best dehydrated when the temperature is maintained in the range of from about 40°C to about 80°C, preferably about 75°C. Alternatively, dehydration of a compound having a carbonyl at carbon atom 6 is best accomplished at elevated temperatures, such as from about 100°C to 130°C. -36Compound XXXIII can then be converted to compounds of the invention as previously described.
Ketone XXX can be reduced to the corresponding alcohol XXXIV using a variety of reducing agents (e.g. NaBH^ in MeOH, LiAlH^ in ether). The alcohol can then be converted to an appropriate leaving group (L) such as halide (e.g. Cl, Br, I) or other derivative (e.g. tosyloxy) thereby providing compound XXXV. For example, the chloride of XXXV (L=C1) can be obtained from the alcohol using SOCI2 in an inert solvent such as toluene.
Alkylation of the appropriately substituted piperazine compound XVI with XXXV then provides XXXVI. The reaction is usually conducted in an inert solvent such as THF or toluene, optionally with base, such as triethylamine or potassium carbonate, typically at ambient to reflux temperature.
XXXVI XIV XXXV -37Compound XXXVI can then be hydrolyzed with any strong aqueous acid, for example 80-95% H2SO4 or HC1 to provide the desired keto compound XXXVII.
XXXVI XXXVII The bridgehead carbonyl of compound XXXVIII or XXXIII may be reduced to an hydroxy group by treating compound XXXVIII with an appropriate reducing agent, such as NaBH4 in CH3OH or LiAlH4 in ether to produce a compound of formula XXXIX.
XXXVIII XXXIX Compounds XXXIX, XXXVII or XXXII may be used to generate other substitutions in the bridgehead using available methods.
When Rc is C(Z)R, these are the compounds of the invention. When Rc is h, CC>2Ra or alkyl, these compounds are converted to compounds of the invention as previously described. -38Another method of making compounds of formula I where Z represents sulfur, comprises reacting a compound of formula I where Z is oxygen with P2S5' Lawesson’s reagent, or another reagent capable of introducing sulfur in place of oxygen.
The reaction may take place at elevated temperature in pyridine, toluene or other suitable solvents. Lawesson’s reagent has the formula In this and other reactions, numerous conversions of a compound of formula I (Z = 0) to another compound of formula I (Z = S) are possible.
In the above processes, it is sometimes 3 desirable and/or necessary to protect certain R , R , R and R^ etc., groups during the reactions. Conventional protecting groups are operable. For example, the groups listed in column 1 of the following table may be protected as indicated in column 2 of the table: -391. Group to be Protected 2. Protected Group -OOOH -COQalkyl, -COObenzyl, -OOOphenyl N-CO2alkyl, N-CO2benzyl, N-CO2CH2QC13 C=& -OH J och3 -nh2 -40Other protecting groups well known in the art also may be used. After the reaction or reactions, the protecting groups may be removed by standard procedures.
The compounds of the invention possess platelet-activating factor (PAF) antagonistic properties. The compounds of the invention are, therefore, useful whenever PAF is a factor in the disease or disorder. This includes allergic diseases such as asthma, adult respiratory distress syndrome, urticaria and inflammatory diseases such as rheumatoid arthritis and osteoarthritis. For example, PAF is an important mediator of such processes as platelet aggregation, smooth muscle contraction (especially in lung tissue), vascular permeability and neutrophil activation. Recent evidence implicates PAF as an underlying factor involved in airway hyperreactivity.
The PAF antagonistic properties of these compounds may be demonstrated by use of standard pharmacological testing procedures as described below. These test procedures are standard tests used to determine PAF antagonistic activity and to evaluate the usefulness of said compounds for counteracting the biological effects of PAF. The in vitro assay is a simple screening test, while the in vivo test mimics clinical use of PAF antagonists to provide data which simulates clinical use of the compounds described herein.
A. PAF Antagonism Assay In vitro Assay: Preparation of platelet-rich plasma (PRP): Human blood (50 ml) was collected from healthy male donors in an anticoagulant solution (5 ml) containing sodium citrate (3.8%) and dextrose (2%). Blood was centrifuged at 110 X g for 15 min. and the supernatant PRP carefully transferred into a polypropylene tube. Platelet-poor-41plasma (PPP) was prepared by centrifuging PRP at 12,000 X g for 2 min. in a Beckman Microfuge B. PRP was used within 3 hours of drawing the blood.
Platelet Aggregation Assay: When an aggregating agent such as PAF is added to PRP, platelets aggregate. An aggregometer quantifies this aggregation by measuring light (infra-red) transmission through PRP and comparing to PPP. The aggregation assays were performed using a dual-channel aggregometer (Model 440, Chrono-Log Corp., Havertown, PA). PRP (0.45 ml) in aggregometer curettes was continually stirred (37°C). Solutions of test compounds or vehicle were added to the PRP, and after incubation for 2 min., 10-15 yl aliquots of PAF solution were added so as to achieve a final concentration of 1-5 X 10 °M. Incubations were continued until the increase in light transmission reached a maximum (usually about 2 min). Values for inhibition were calculated by comparing maximal aggregation obtained in the absence and the presence of the compound. For each experiment, a standard PAF antagonist, such as alprazolam, was used as a positive internal control. The inhibitory concentration (IC3q) is the concentration of compound in micromoles at which 50% of the aggregation is inhibited, as measured by the light transmission through each sample of PRP as compared to PPP. The test results are shown below in Tables la, lb and Ic.
PAF is also a known bronchoconstrictive agent in mammals. Hence, PAF antagonism can be evaluated by measuring inhibition by the compounds of the invention in PAF-induced bronchoconstriction in guinea pigs. -42B. PAF-Induced Bronchospasm in Guinea Pigs In Vivo Assay Non-sensitized guinea pigs were fasted overnight, and the following morning were anesthetized with 0.9 ml/kg i.p. of dialurethane (0.1 g/ml of diallybarbituric acid, 0.4 g/ml of ethylurea and 0.4 g/ml of urethane). The trachea was cannulated and the animals were ventilated by a Harvard rodent respirator at 55 strokes/min. with a stroke volume of 4 ml. A side arm to the tracheal cannula was connected to a Harvard pressure transducer to obtain a continuous measure of intratracheal pressure, which was recorded on a Harvard polygraph. The jugular vein was cannulated for the administration of compounds. The animals were challenged i.v. with PAF (0.4 ug/kg in isotonic saline containing 0.25% BSA) and the peak increase in inflation pressure that occurred within 5 min. after challenge was recorded. Test compounds were administered either orally (2 hrs. prior to PAF as a suspension in 0.4% methylcellulose vehicle) or intravenously (10 min. prior to PAF as a solution in dimethylsulfoxide).
The compound 8-chloro-ll-(l-acetyl-4piper idylidene) - 6, ll-dihydro-5ji-benzo(5,6] cyclohepta [1,2b]pyridine at a dose of 1 mg/kg given intravenously inhibited PAF-induced bronchospasm by 75% as measured by this procedure. Similarly, the compound 8-fluoro-11-(1acetyl-4-piperidylidene)-6,11-dihydro-5H-benzo[5,6] cyclohepta[l,2-b]pyridine when administered at 3 mg/kg (iv) inhibited PAF-induced bronchospasm by 99%. The compound 9-fluoro-ll-(l-acetyl-4-piperidylidene)-6,11di hydro-5li-benzo [5,6]cyclopheta[1,2-b]pyridine when administered at 3 mg/kg (iv) inhibited PAF-induced bronchospasm by 97%. -43The compounds of the invention also possess antihistaminic properties which may be assessed by test procedure C below. Test procedure C, Prevention of histaminic-induced lethality demonstrates basic antihistaminic activity of representative compounds of structural formula I. Protection against histamine lethality is indicative of strong antihistaminic properties.
Test procedures D, E and F demonstrate the extent of CNS activity induced by the compounds of the invention. The presence of strong CNS activity indicates a high probability of sedation caused by the compounds, a typically undesirable side effect of antihistamines. Consequently, a low level of CNS activity is preferred in most circumstances.
C. Antihistamine Activity Assay Prevention of Histamine-Induced Lethality in Guinea Pigs. Some of compounds shown below in Table I also were evaluated for antihistamine activity by their ability to protect female albino guinea pigs (250-350 g) against death induced by the intravenous injection of histamine dihydrochloride at 1.1 mg/kg, which is approximately twice the LDgg. Doses of the antagonists were administered orally to separate groups of fasted animals 1 hour prior to the challenge with histamine and protection from death recorded for 30 minutes after histamine. EDjq values were determined for each drug by probit analysis.
CNS Activity Assays D. Antagonism of Physostigmine Lethality. The physostigmine-induced lethality test is indicative of CNS activity and the test described is a modification of the technique reported by COLLIER et al., Br. J. Pharmac., 32, 295-310 (1968). Physostigmine salicylate (1.0 mg/kg -44s.c.) produces 100% lethality when administered to mice grouped 10 per plastic cage (11 x 26 x 13 cm). Test agents were administered orally 30 minutes prior to physostigmine. The number of survivors were counted 20 minutes after physostigmine administration.
E. Antagonism of Acetic Acid Writhing. The acetic acid writhing test is a second test useful for determining CNS activity, and is essentially that described by HENDERSHOT and FORSAITH, J. Pharmac. Exp.
Ther., 125, 237-240 (1959), except that acetic acid rather than phenylquinone was used to elicit writhing. Mice were injected with 0.6% aqueous acetic acid at 10 mg/kg i.p. 15 minutes after oral administration of the test drug. The number of writhes for each animal was counted during a 10 minute period starting 3 minutes after acetic acid treatment. A writhe was defined as a sequence of arching of the back, pelvic rotation and hind limb extension.
F. Antagonism of Electro-Convulsive Shock (ECS). The ECS test is a third test useful for determining CNS activity. For the ECS test, a modification of the method of TOMAN et al., J. Neurophysiol·., 9, 231-239 (1946), was used. One hour after oral administration of the test drug or vehicle, mice were administered a 13 mA, 60 cycle a.c. electroconvulsant shock (ECS) for 0.2 seconds via corneal electrodes. This shock intensity produces tonic convulsions, defined as extension of the hind limbs, in at least 95% of vehicle-treated mice.
Of the above test procedures for measuring CNS activity, the physostigmine-induced lethality test is believed to be a major index of non-sedating characteristics, since it reflects mainly central anticholinergic potency which is believed to contribute to sedative activity.
Representative results of these test procedures with compounds of the invention are presented below in Tables IA, IB and IC.
TABLE ΙΑ Compound Antihistaminic Activity CNS Activity PAF Antagonism (in vitro) to "IL A ir * Guinea pig oral dose (mgAg) Dose % Survival Physostigmine lethality Acetic writhing Λ ECS test A Dose (micromoles) % PAF Antagonism Z=S, R=Ph RJ=C1, R4=H 5 PO 60 >320 >320 >320 * ft 1 PO 0 2=0 R=CHn R3=C1 r4=h 5 PO 1 PO 100 60 >320 >160 >320 0.7 50 Z=O R=Ph r3=ci r4=h 5 PO 1 PO 100 0 ft * * 10 9 5 PO 1 PO 80 80 >320 >320 >320 6 50 z=o 5 PO 1 PO 100 40 >320 >320 >320 * ft z=o R=-SCH2CH? r3=ci rM 5 PO 1 PO 80 100 >320 >320 >320 10 0 2=0 TABLE IA (continued) Compound Antihistaminic Activity CNS Activity PAF Antagonism (in vitro) Guinea pig oral dose (mgAg) Dose % Survival Physostigmine lethality A) Acetic writhing ECS test Dose (micromoles) % PAF Antagonism s R=CH9CH-j r3=ci r4=h Z=O 5 PO 1 PO 80 40 >320 >320 >320 3 60 r3=f r4=h 2=0 5 PO 1 PO 100 100 <320 <320 <320 10 9 R=-CHo 2=0 r3=f r4=h 5 PO 20 * * * 0.7 50 R=-CH9 2=0 r3=h r4=f 5 PO 01 * * * 0.9 50 σ> ι TABLE IA (continued) Antihistaminic Activity Guinea pig oral dose (mgAg) Dose % Survival CNS Activity Physostigmine Acetic ECS lethality writhing test _ PAF Antagonism (in vitro) Dose (micromoles) % PAF Antagonism R3=Br, R4=H, r=ch3 z=o 1.2 50 R3, R4= "λ R=CHq V=y z=o 5 35 r3=ci, r4=h r=ch=ch2 z=o 25 63 r3=ci, r4=h r=nhch^ zo 50 29 Compound r=ch3 Z=O A=OH r3=ci, r4=h r=ch3 Z=O a=ch3 r3=ci, r4=h r=ch3 z=o A=Keto r3=h, r4=h A=H CZR=CH3** R^OC2h5** r3=ci, r4=h Z=O TABLE IA (continued) Antihistaminic Activity CNS Activity PAF Antagonism (in vitro) Guinea pig oral dose (mgAg) Dose % Survival Physostigmine lethality A Acetic writhing ED50 (mg/kg) ECS test A Dose (micromoles) % PAF Antagonism 5 50 1.0 50 1.2 50 o?S89= 6.1 8.9 >80 >100 50 >320 >320 >320 175 50 *Not Tested **Standard Known Antihistamine 1 Expected to have sone activity at a higher dose TABLE IB PAF Antagonism (in vitro) Compound r3=h, r4=h R=CH. Z=O X=CH R3=C1, X=N R=CH-, Z=0 R4=H R3=C1, X=N R=H Z=O R4=H R3=C1, X=N R=€H2OCH3 Z=O Dose (micromoles) % PAF Antagonism 5 50 .5 43 5 50 5 50 5 63 * Not tested ** Standard known antihistamine Conpound TABLE IC PAF Antagonism (in vitro) Dose % PAF (micromoles) Antagonism .5 50 -51As seen from the data of Tables IA, IB and IC and from the PAF induced bronchospasm inhibition test results, the compounds of structural formula I exhibit PAF antagonist and antihistaminic properties to varying degrees, i.e., certain compounds have strong PAF antagonistic activity, but have weaker antihistaminic activity. Other compounds are strong antihistamines but weaker PAF antagonists. Several of the compounds are both strong PAF antagonists and potent antihistamines. Consequently, it is within the scope of this invention to use each of these compounds when clinically appropriate. For example, if a strong PAF antagonist is required, but weaker antihistaminic activity is necessary, such a compound could be chosen by the clinician. Alternatively, if both potent PAF antagonism and antihistaminic activity are required, a different compound of the invention would be utilized by the clinician.
For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 70 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar, lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify. -52Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection.
Liquid form preparations may also include solutions for intranasal administration.
Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
Preferably the compound is administered orally.
Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, more preferably from about 1 mg. to 100 mg, according to the particular application. The appropriate dosage can be determined by comparing the activity of the compound with the activity of a known antihistaminic compound such as 8-chloro-6,11-dihydro-ll(l-ethoxycarbonyl-4-piperidylidene) -5_H-benzo[5,6] -53cyclohepta[1,2-b]pyridine, which compound is disclosed in U.S. Patent No. 4,282,233.
The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
The amount and frequency of administration of the compounds of the invention and the pharmaceutically acceptable salts thereof will be requlated according to the judgement of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptom being treated. A typical recommended dosage regimen is oral administration of from 10 mg to 1500 mg/day preferably 10 to 750 mg/day, in two to four divided doses to achieve relief of the symptoms. The compounds are non-toxic when administered within this dosage range.
The following examples are intended to illustrate, but not to limit, the present invention. -54PREPARATIVE EXAMPLE I A. N- (1,1-DIMETHYLETHYL)-3-METHYL-2-PYRIDINE CARBOXAMIDE nhc(ch3) 3 Suspend 2-cyano-3-methyl pyridine (400 g) in tbutanol (800 mL) and heat to 70°C. Add concentrated sulphuric acid (400 mL) dropwise over 45 minutes.
Maintain the temperature at 75°C, until the reaction is complete, and for an additional 30 minutes. Dilute the mixture with water (400 mL), charge with toluene (600. mL) and bring to pH 10 with concentrated aqueous ammonia. Maintain the temperature at 50-55°C during the work up. Separate the toluene phase, and reextract the aqueous layer. Combine toluene phases and wash with water.
Remove the toluene to yield the title compound IJ-(1,1dimethylethyl·)-3-methyl-2-pyridine carboxamide, as an oil, from which solid product is crystallized. (Yield 97%, as determined by an internal standard assay with gas chromatography).
B. 3-(2-(3-CHLOROPHENYL)ETHYL]-N-(1,1-DIMETHYLETHYL)-2PYRIDINE CARBOXAMIDE Dissolve the title compound of Preparative Example ΙΑ, N-(1,1-dimethylethyl)-3-methyl-2-pyridine carboxamide (31.5 g.) in tetrahydrofuran (600 mL) and -55cool the resulting solution to -40°C. Add n-butyllithium (2 eg.) in hexane while maintaining the temperature at -40eC. The solution turns deep purple-red. Add sodium bromide (1.6 g) and stir the mixture. Add solution of mchlorobenzylchloride (26.5 g., 0.174 mole) in tetrahydrofuran (125 mL) while maintaining the temperature at -40°C. Stir the reaction mixture until the reaction is complete as determined by thin layer chromatography. Add water to the reaction until the color is dissipated. Extract the reaction mixture with ethyl acetate, wash with water, and concentrate to a residue which is the title compound. (Yield 92% as shown by chromatography).
C. 3-(2-(3-CHLOROPHENYL)ETHYL]-2-PYRIDINE-CARBONITRILE Heat a solution of the title compound of Preparative Example IB, 3-(2-(3-chlorophenyl)ethyl]-N(l,l-dimethylethyl)-2-pyridine carboxamide (175 g, 0.554 mole) in phosphorous oxychloride (525 mL, 863 g, 5.63 mole) and reflux for 3 hours. Determine completion of the reaction by thin layer chromatography. Remove any excess phosphorous oxychloride by distillation at reduced pressure and quench the reaction in a mixture of water and isopropanol. Bring to pH 5-7 by adding 50% aqueous sodium hydroxide solution while maintaining the temperature below 30°C. Filter the crystalline slurry of crude product and wash with water. Purify the crude product by slurrying the wet cake in hot isopropanol, and -56cool to 0-5°C. Filter the product, wash with hexane and dry at a temperature below 50°C to yield the title compound. (Yield: 118g (HPLC purity 95.7%), m.p. 72°C73°C, 89.4% of theory).
D. 1-(METHYL-4-PIPERIDINYL)[3-(2-(3-CHLOROPHENYL)ETHYL)2-PYRIDINYL]METHANONE HYDROCHLORIDE Dissolve the title compound of Preparative Example 1C, (118 g, 0.487 mole) in dry tetrahydrofuran (1.2L) and add N-methyl-piperidyl magnesium chloride (395 mL, 2.48 mole/liter, 0.585 mole, 1.2 eq.) over 15 minutes. Maintain the temperature at 40°C-50°C by cooling withwater as necessary, for 30 minutes.
Determine completion of the reaction by thin-layer chromatography. Quench the reaction by reducing the pH to below 2 with 214 HC1 and stir the resulting solution at 25°C for 1 hour. Remove the bulk of the tetrahydrofuran by distillation and adjust the resulting solution to pH 3.5 by addition of aqueous sodium hydroxide. Cool to 0 to 5°C and filter off the crystalline hydrochloride salt product. Wash with ice cold water and dry to constant weight at 60°C to yield the title compound. (Yield: 168.2 g (HPLC purity 94%), m.p. 183°-185°C, 89% of theory). -57E. 8-CHLORO-ll-(1-METHYL-4-PIPERIDYLIDENE)-6,11DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE Dissolve the title compound of Preparative Example ID above (59 g, 0.15 mole) in hydrofluoric acid (120 mL, 120 g, 6.0 mole) at -35°C and add boron trifluoridine (44.3 g, 0.66 mole) over 1 hour. Determine completeness of the reaction by thin-layer chromatography. Quench the reaction using ice, water and potassium hydroxide bringing the solution to a final pH of 10. Extract the product with toluene and wash with water and brine. Concentrate the toluene solution to a residue, and dissolve in hot hexane. Remove the insolubles by filtration and concentrate the filtrate to yield the title compound as an off-white powder.
(Yield: 45.7 g (HPLC purity: 95%), 92% of theory).
Alternative Step E: 8-CHLORO-ll-(1-METHYL4-PIPERIDYLIDENE)-6,11-DIHYDRO-5H-BENZO[5,6] CYCLOHEPTA[1,2-b]-PYRIDINE React the title compound of Preparative Example ID above (177 g, 0.49 mole) in trifluoromethanesulfonic acid (480 ml, 814.1 g, 5.31 mole) at 90-95°C for 18 hours under nitrogen. Determine the completeness of the reaction by thin-layer chromatography. Cool the reaction and quench the reaction with ice—water and adjust the pH to 6 with barium carbonate. Extract the product with methylene chloride, and concentrate under reduced pressure to about 1 liter. Wash with water, and extract -58the product into 1 _N HCl which is treated with 30 g of activated charcoal, and filter through celite. Adjust the pH of the filtrate to 10 with aqueous sodium hydroxide (50%), extract the product into methylene chloride, and remove under reduced pressure to form a residue. Dissolve the residue in hot hexane, and filter to remove insolubles. Concentrate the filtrate to yield the title compound as a beige powder. (Yield: 126 g (HPLC purity 80%), 65% of theory).
F. 8-CHLORO-ll-(1-ETHOXYCARBONYL-4-PIPERIDYLIDENE)-6,11DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE Dissolve the title compound of Preparative Example IE above (45.6 g, 0.141 mole) in toluene (320 mL) at 80°C and to it gradually add ethyl chloroformate (40.4 mL, 45.9 g, 0.423 mole). Following complete addition, maintain the temperature at 80°C for 1 hour, then add diisopropylethylamine (2.7 mL, 2.00 g, .016 mole) and additional ethyl chloroformate (4.1 mL, 4.65 g, 0.0429 mole). Monitor completeness of the reaction by thin layer chromatography. Upon completion, cool the reaction mixture to ambient temperature, and wash the toluene solution with water. Concentrate the organic layer to a residue and dissolve in hot acetonitrile (320 mL). Decolorize the solution with 14 g of activated charcoal. Remove the activated charcoal by filtration and concentrate the filtrate to a crystalline slurry.
Cool the mixture to 0-5°C, and isolate the product by -59filtration. Wash with cold acetonitrile and dry the product at below 70°C to yield the title compound. (Yield: 42.4 g (HPLC purity 97.4%), 80% of theory).
G. 8-CHLORO-ll-(4-PIPERIDYLIDENE)-6,11-DIHYDRO-5HBENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE Hydrolize the title compound of Preparative Example IE, 8-chloro-ll-(l-methyl-4-piperidylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta[l,2-b]pyridine (39 g, 0.101 mole) with KOH (50 g) in ethanol (305 mL) and water (270 mL) at reflux under an argon atmosphere for 64 hours. Partially distill off the ethanol and dilute the residue with brine, and extract with ethylacetate (3x). Wash the combined organic phases with water and dry with Na2SO4· Remove the solvent to give a solid which can be recrystallized from toluene to give the title compound as a white solid. (Yield: 24.5 g, 77%, melting point 154-155°C).
H. By substituting in step IB above, an appropriately substituted aryl or alkyl halide listed in Table II below for meta-chlorobenzylchloride, and employing basically the same methods as steps C through G, the products listed in Table II are prepared by the process of Preparative Example 1 above. Reaction times are determined by TLC or HPLC. In some instances purification of the product by chromatography is necessary. -60TABLE II halide Product of step G Melting Point ch3i Then repeat step r3=f, r4=h, A=H 133.5-134.5°Ca r3=ci, r4=ci, A=H 150-152°Cb r3=ch3, r4=h, A=H 142-144°Cc R3=Br, r4=h, A=H 146-148°C r3=och3 , R4=H, A=H crude solid R3, R4r 3' A=H glass B with R3=C1, r4=h, a= ch3 glass a Step E required trifluoromethanesulfonic acid. Recrystallized from toluene. c Recrystallized from acetone and pentane. -61PREPARATIVE EXAMPLE 2 PREPARATION OF 9-FLQORO-ll-(4-PIPERIDYLIDENE)-6,115 DIHYDRO-5H-BENZO [5,6] CYCLOHEPTA [ 1,2-b] PYRIDINE A. N- (1,1-DIMETHYLETHYL) -3-(2-( 4-FLUOROPHENYL) ETHYL] -2PYRIDINE CARBOXAMIDE Cool a solution of N-(1,1-dimethylethyl)-3methyl-2-pyridinecarboxamide (38.4 g, 0.2 mole) in dry THF (250 mL) to -40°C and add n-butyl lithium (185 mL, 0.44 mole). Add sodium bromide (1.9 g, 18 mmol.) and stir for 15 "ninutes. Add 4-fluorobenzylchloride (31.8 g 0.22 mole) and stir for 2.5 hours while warming to -5°C. Quench the reaction with water and extract the product twice with ethyl acetate, then wash with brine (2X) . Dry the organic phase over Na2SO^, filter and remove the solvent to give the title compound. (60.0 g, Yield 99%, m.p. 59-61°C.) B. 3-[2-(4-FLUOROPHENYL)ETHYL]-2-PYRIDINE CARBONITRILE NH C(CH3) 3 -62Heat the title compound of Preparative Example 2A above (60.0 g,0.2 mole) in POCI3 (200 mL) to 110°C under an argon atmosphere for 3.5 hours. Pour the reaction mixture onto ice and basify with NaOH (50%) solution. Extract the mixture with ethyl acetate (3x) and wash with water. Wash with brine and dry over Na.2SO4· Remove the solvent and pass the residue through a coarse S1O2 (60-200 mesh) column to give the title compound as a white solid (40 g, Yield 88%, m.p. 4849°C.).
C. 9-FLUORO-5,6-DIHYDRO- (lH) -BENZO [5,6] CYCLOHEPTA [1,2b]PYRIDIN-ll-ONE Cyclize the title compound of Preparative Example 2B above (31.5 g, 139 mmol) in polyphosphoric acid (1.24 kg) at 200°C for 5.5 hours. Pour onto ice and' basify with NaOH solution (50%). Extract the product with chloroform (3x) and wash with brine. Dry the organic phase with Na2SO4, filter and remove the solvent to give the title compound (20.4 g, yield 64%, m.p. 7881°C after recrystallization from diisopropyl ether). -63D. 9-FLUORO-ll-(1-METHYL-4-PIPERIDINYL)-6,11-DIHYDR0-5HBENZO[5,6]CYCLOPHEPTA[1,2-b]PYRIDIN-ll-OL Dissolve the title compound of Preparative Example 2C above (10.0 g, 44 mmol) in THF (100 mL) and add slowly to a cooled (-40*0 solution of the Grignard reagent prepared from N-methyl-4-chloro-piperidiene (57.9 mL, 88 mmol) in THF (70 mL). Stir the mixture for about 1 hour while warming up to 0°C. Quench the reaction with NH^Cl solution and extract with ethyl acetate (2x). Wash the organic phase with brine and dry over Na2SO4, filter and remove the solvent. Purify the residue with flash chromatography and elute with methanol (5%) in CHC13 to give the titfe compound as white granular crystals. (10.1 g, Yield 70%, m.p. 126-127°C after recrystallization from diisopropyl ether.) E. 9-FLUORO-ll-(1-METHYL-4-PIPERIDYLENE)-6,11-DIHYDRO25 5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE Add the title compound of Preparative Example 2D above (7.3 g, 22.3 mmol) to a mixture of cooled H2SO4 -64and CF3SO3H (1:1), 146 mL). Stir the reaction mixture for 0.5 hours at ice bath temperature and then at room temperature for 1.5 hours. Pour the reaction mixture onto ice and basify with NaOH (50%) solution. Extract the product with ethyl acetate (3x) and wash with brine. Dry the organic phase over Na2SO4, filter and remove the solvent to give a crude oil. Charcoal the oil and recrystallize from ethyl acetate and isopropyl ether to give the title compound. (5.6 g, Yield 82%, m.p. 134.510 135.5°C.).
F. 9-FLDORO-11-(1-ETHOXYCARBONYL-4-PIPERIDYLIDENE)-6,11DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE Stir a solution of the title compound of Preparative Example 2E above (5.0 g, 16.2 mmol) and triethylamine (2.6 g, 26 mmol) in dry toluene (60 mL) at 80°C under an argon atmosphere, and add ethylchloroformate (9.8 g, 90 mmol) via a syringe. Stir the reaction at this temperature for 30 minutes and at room temperature for one hour. Filter the reaction and remove the solvent. Pass the residue through a coarse SiO2 column (60-200 mesh), and elute with CHCI3 to yield the title compound as a white solid. (4.5 g, Yield 76%, m.p. 112-114°C after trituration with pentane). -65G. 9-FLUORO-ll-(4-PIPERIDYLIDENE)-6,11-DIHYDRO-5HBENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE Reflux the title compound of Preparative Example 2F above (3.83 g, 10.4 mmol) with KOH (4.6 g) in 50 mL of ethanol/H20 (1:1) for 4 hours under an argon atmosphere. Pour the reaction mixture into a brine solution and extract with ethyl acetate (2x), dry over Na2SO^ and filter. Remove the solvent to give the title compound (2.86 g, Yield 90%, m.p. 138-140°C.).
H. By employing the appropriately substituted benzyl halide listed in Table III in place of 4-fluorobenzyl chloride in step 2A above, the desired products shown in the second column of Table III are prepared by employing basically the same process as described in steps 2A-2G. Workup time is determined by either TLC or HPLC. In some instances purification of the product by chromatography is necessary. -66TABLE III Product Benzyl Halide of Step G Melting Point 134-135°Ca 138-140°Cb 120-122eCb 123-124C0a Recrystallized from ethyl acetate and pentane. b Triturated with pentane. -67PREPARATIVE EXAMPLE 3 A. 6,ll-Dihydro-ll-(l-methyl-4-piper idylidene)-5Hbenzo[5,6]cyclohepta[1,2-c]pyridine The compound 5,6-dihydro-llH-benzo[5,6] cyclohepta[l,2-c]pyridine-ll-one, may be prepared by following the methods described in U.S. Patent No. 3,419,565. This ketone may be converted to the title compound by the methods previously described in Preparative Example 2, steps D and E.
B. 11-(l-Cyano-4-piperidylidene)-6,11-DIHYDRO-5Hbenzo[5,6]cyclohepta[1,2-c]pyridine To a solution of 400 mg (1.35 mmole) of 11-(l-methyl-4piperidylidene) -6,11-dihydro-5_H-benzo[5,6] cyclohepta [1,2-c]pyridine in 5.0 mL of benzene at room temperature and under an argon atmosphere was added dropwise a solution of 168 mg (1.59 mmole) of cyanogen bromide in 4 mL of benzene. After 30 min. the mixture was poured into water and extracted once with EtOAc. The organic layer was isolated, washed once with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified via flash chromatography [2^ MeOH in CH2C12] to give 150 mg (37%) of the title compound as a solid: m.p. 212-214°C. -68C. 11-(4-piperidylidene)-6,ll-dihydro-5Hbenzo[5,6]cyclohepta[1,2-c]pyr idine A mixture of 140 mg (0.46 mmole) of 11-(l-cyano-4piper idylidene)-6,ll-dihydro-SH^benzo[5,6]cyclohepta[1,2c]pyridine in 20 mL of 30% aqueous HCl was refluxed for about 22½ hrs. The mixture was poured into ice water, basified with 25% aqueous NaOH, and extracted twice with CH2CI2. The combined organic portions were dried over Na2SO4» filtered, and concentrated in vacuo. The product was purified via flash chromatography [5% MeOH saturated with NH3 in CH2CI2] to give 95 mg (75%) of the title compound as a glass.
PREPARATIVE EXAMPLE 4 A. 8-Chloro-llH-benzo[5,6]cyclohepta[1,2b]pyridin-ll-one :i -69Reflux a mixture of 8-chloro-5,6-dihydro-1Hbenzo[5,6]cyclohepta[l,2-b]pyridin-ll-one (25.99 g, 0.107 mol.), recrystallized N-bromosuccinimide (21.35 g, 0.120 mol) and 167 mg (.102 mmol) of azobisisobutyrylnitrile in 400 mL of carbontetrachloride under an argon atmosphere for 1.25 hours. Cool the solution slowly to 50°C and filter off the resultant precipitate.
Reflux the precipitate with 1,8-diazabicyclo [5.4.0]undec-7-ene (DBU) (20 mL, 0.134 mol) in CH2Cl2 (400 mL) for 1 hour. Wash with water (3X), dry over magnesium sulfate, filter and concentrate in vacuo. Recrystallize the crude product from Cl^C^/toluene to give the title compound as colorless needles (8.93g, yield 35%).
B. 8-Chloro-ll-(l-methyl-4-piperidinyl)-11Hbenzo[5,6]cyclohepta[1,2-b]pyr idin-ll-ol To a mixture of 22 mL of 0.5M Grignard reagent of N-methyl-4-chloropiperidiene (11.0 mmole) in THF at -45°C and under a nitrogen atmosphere was added dropwise over 15 min. a solution of 1.06 gm (4.39 mmole) of 8chloro-llja-benzo[5,6] cyclohepta [1,2-b] pyr idin-ll-one in 23 mL of dry THF. After 2 hr. 40 min. the reaction mixture was poured into water and extracted three times with EtOAc. The organic portions were combined, washed two times with brine, dried over MgSO^/ filtered, and concentrated in vacuo. The residue was purified via -70flash chromatography [10% MeOH in CH2Cl2] to give 970 mg (65%) of the title compound as a glass.
C. 8-Chloro-11-(l-methyl-4-piperidilidene)-11Hbenzo[5,6]cyclohepta[1,2-b]pyridine A mixture of 847 mg (2.48 mmole) of 8-chloroll- (1-methy1-4-piper idinyl) -llH-benzo[5,6]cyclohepta[1,2b]pyridin-ll-ol in 5 mL of concentrated sulfuric acid and 5 mL of trifluoromethane sulfonic acid was heated at 70°C for 4 hr 10 min. The mixture was cooled to room temperature, poured into ice cold 30% aqueous KOH, and extracted three times with CH2C12. The organic portions were combined, washed once with water, dried over MgSO^, filtered, and concentrated in vacuo to yield 755 mg (94%) of the title compound as a glass.
D. 8-Chloro-ll-[1-(2,2,2-tr ichloroethoxycarbonyl)4-piper idylidene)-llH-benzo[5,6] cyclohepta[1,2-b] pyr idine -71To a mixture of 755 mg (2.34 mmole) of 8chloro-ll-( l-methyl-4-piperidylidene )-ll_H_-benzo [5,6] cyclohepta[1,2-b]pyridine and 1.5 mL of triethylamine in 25 mL of dry toluene at room temperature and under a nitrogen atmosphere was added 650 uL (4.72 mmole) of 2,2,2-trichloroethyl chloroformate. The mixture was then heated to 90°C. Additional amounts of the chloroformate (500 uL and 300 uL) and triethylamine (1.0 mL each time) were added to the mixture after 2 hr. and 3 hr. 40 min., respectively. After a total reaction time of 5 hr. the mixture was poured into water and extracted three times with CH2CI2. The combined organic portions were dried over MgSO^, filtered and concentrated in vacuo. The residue was purified via flash chromatography [lV^i MeOH in CH2C12] to afford 639 mg (56%) of the title compound as a glass.
E. 8-Chloro-l1-(4-piperidylidene)-llH-benzo[5,6] cyclohepta [1,2-b]pyridine A mixture of 210 mg (0.434 mmole) of 8-chloro30 11- [1-(2,2,2-trichloroethoxycarbonyl)-4-piperidylidene)lHL-benzo[5,6]cyclohepta[1,2-b]pyridine and 526 mg (8.05 mmole) of zinc dust in*4 mL of acetic acid was heated at 60-70°C. After 2 hr. 20 min. another 547 mg (8.37 mmole) of zinc dust was added. After another 30 min. the mixture was basified with 10% aqueous NaOH and extracted four times with CH2C12· The combined organic portions -72were washed once with water, dried over MgSO^, filtered, and concentrated in vacuo. The residue was purified via flash chromatography [5*6% MeOH/NH3 in CHCI3] to yield 71 mg (53%) of the title compound as a glass.
PREPARATIVE EXAMPLE 5 A. 5-Methoxy-8-chloro-llH-benzo[5,6]cyclohepta[1,2b]pyridin-ll-one B. 6-Methoxy-8-chloro-llH-benzo[5,6]cyclohepta[1,2blpyridin-ll-one Add Br2 (5.10 mL, 99 mmol) to a mixture of 8chloro-llH_-benzo [5,6] cyclohepta [1,2-b]pyridin-ll-one (8.15 g, 33.7 mmol) and powdered AgNO3 (23.19 g, 137 mmol) in 300 mL of dry methanol at room temperature under an argon atmosphere. After 8 hours, add additional AgNO3 (5.90 g, 34.7 mmol) followed by additional Br2 (1.7 mL, 33.0 mmol). After 0.5 hours pour the mixture into water and extract (4X) with CH2C12. Combine the organic phases, dry over magnesium sulfate, filter and concentrate in vacuo to give a mixture of the crude bromo ethers .
Dissolve the crude product in CH2C12 (200 mL) at room temperature and place under an argon atmosphere. Add DBU (20 mL, 134 mmol) and reflux for 1.3 -73hours. Add additional DBU (10 mL, 67 mmol) and reflux the mixture for an additional hour. Pour the mixture into water and extract (3X) with CH2C12. Combine the organic phases, wash with water and dry over magnesium sulfate. Filter and concentrate in vacuo. The two isomeric vinyl ethers, title compounds A and B, are separated via flash chromatography (40% - 75% ethyl acetate in hexanes] and recrystallize from ethyl acetate hexanes to give title compound A (1.51 g, 14.3%, mp 156 to 158°C) and title compound B (3.68 g, 35%, mp 161 to 162°C).
C. S-Methoxy-S-chloro-ll-(l-methyl-4-piperidinyl)-11Hbenzo (5,61cyclohepta[1,2-b]pyridin-ll-ol Add a 1.5 M Grignard solution of N-methyl 4chloropiperidine (150 mL, 22.5 mmol) in THF dropwise over a 7 minute period to 5-methoxy-8-chloro-llH-benzo[5,6] cyclohepta[1,2-b]pyridin-ll-one (5.00 g, 18.4 mmol) in THF (70 mL) at 0°C and under an argon atmosphere. Quench the reaction after 30 minutes with a saturated solution of NH4CI (pH 8) and extract (3X) with CHCI3. Combine the organic portions, wash with brine, dry over sodium sulfate, filter and concentrate in vacuo. Purify via flash chromatography (CH3OH 5% in CH2C12) to give the title compound (3.60 g, 53%) as a solid. The solid may be recrystallized from isopropyl ether to give a white powder (mp 168-170°C). -74D. 8-Chloro-ll-(l-methyl-4-piperidylidene)-6,11-dihydro5H-benzo[5,61cyclohepta[1,2-b]pyridin-5-one o Dissolve 5-Methoxy-8-chloro-ll-(1-methy1-4piperidinyl)-llH-benzo[5,6]cyclohepta[1,2-b]pyridin-ll-ol (4.26 g) in CH^OH (6 mL) at 0°C under an argon atmosphere. Add slowly a cooled solution of 92% aqueous H2SO4 (54 mL). Allow the mixture to warm to room temperature for 35 minutes. Pour the solution onto ice, basify with aqueous NaOH (25%), and extract with methylene caloride (3X). Combine the organic portions, wash with brine and dry over sodium sulfate. Filter and concentrate in vacuo. Triturate the residue with ispropyl ether to give an intermediate, 8-chloro-llhydroxy-ll-(1-methy1-4-piperidinyl)-6,1l-dihydro-SjL·benzo [5,6]cyclohepta[1,2-b]pyridin-5-one as a white solid (3.58 g., 92%, m.p. 170 to 174°C as HCl salt).
Dissolve the intermediate compound (3.58 g .0 mmol) in trifluoromethane sulfonic acid (50 mL) and heat to 45°C under an argon atmosphere for 3 hours. Pour the mixture onto ice, basify with aqueous NaOH (25% w/v), and extract with CHCI3 (3X). Combine the organic portions, wash with brine and dry over sodium sulfate. Filter and concentrate in vacuo. Chromatograph on silica gel (5% CH3OH in CH2C12) to 9ive the title compound as an off white solid (1.703 g, 50%, 58% based on recovered -75starting material). An analytical sample was prepared by recrystallization of the product with ethyl acetate/ isopropyl ether (mp 162-163°C).
E. Ethyl-4-(8-chloro-5-ethoxycarbonyloxy-llHbenzo[5,6]cyclohepta[l,2-b]pyridin-11-ylidene)-1piperidine carboxylate o N ' Me Dissolve the 8-Chloro-ll-(l-methyl-4piperidylidene)-6,ll-dihydro-5H-benzo[5,6]cyclohepta[1,2b]pyridin-5-one (617 mg, 1.82 mmol) and triethylamine (0.50 mL, 3.58 mmol) in toluene (12 mL) at 80°C under an argon atmosphere. Add dropwise over 2 minutes ethyl chloroformate (0.87 mL, 9.10 mmol). After 25 minutes cool the mixture to room temperature, filter, and concentrate in vacuo. Purify the crude product via flash chromatography (1% CH^OH in CH2CI2) to yield the title compound as a glass (834 mg, 98%) . -76F. 8-Chloro-ll-(4-piper idylidene)-6,ll-dihydro-5Hbenzo[5,6]cyclohepta[1,2-b]pyridin-5-one Mix ethyl 4-(8-chloro-5-ethoxycarbonyloxy-llHbenzo[5,6]cyclohepta[1,2-b]pyridin-ll-ylidene)-1-piper idine carboxylate (897 mg, 1.91 mmol) and aqueous KOH (20 mL, 13% w/v) in ethanol (15 mL) and reflux under an argon atmosphere for 25 hours. Pour the mixture into water and extract with CHC13 (3X). Combine the organic portions, wash with brine, dry over sodium sulfate, filter, and concentrate in vacuo. Purify the residue via flash chromatography (2% CH^OH saturated with NH3 in CH2CI2) and triturate with isopropyl ether to give the title compound as a white solid (417 mg, 67%, mp 194-f96°C (dec)).
G. S-Hydroxy-S-chloro-ll-(4-piper idylidene)-6,11-dihydro5H-benzo[5,6]cyclohepta[1,2-b]pyridine Mix 8-Chloro-ll-(4-piper idylidene)-6,11-dihydro5H-benzo[5,6]cyclohepta[1,2-b]pyridin-5-one (400 mg, 1.23 mmol) in CH30H (20 mL> at °°c under an argon atmosphere, and add in 3 portions NaBH4 (total 231 mg, 6.10 mmol). After 30 -77minutes, pour the mixture into water and extract (3X) with ethyl acetate. Combine the organic portions, wash with brine, dry over sodium sulfate, filter and concentrate in vacuo. Triturate the solid with isopropyl ether/ethyl acetate to give the title compound as a white solid (351 mg, 87%).
PREPARATIVE EXAMPLE 6 8-Chloro-ll((Z)-2,5-dimethyl-4-piperidylidene)-6,11di hydro- 5H-benzo [5,6]cyclohepta(1,2-b]pyr idine A. 1,2,6-trimethyl-4-chloropiperidine OH The starting material, 1,2,6-trimethyl-4piperidinol, may be prepared by the method disclosed in Archi Kern, Volume 27, pages 189-192 (1955). To a cooled (ice-bath) solution of 1,2,6-trimethyl-4-piperidinol (12.2g, 85.3 mmol) in 120 mL of dry benzene was slowly added thionylchloride (17 mL, 233 mmole). The dark reaction mixture was then warmed to 70°C for 20 min. The reaction was cooled and then suspended in water followed by filtration. The filtrate was extracted once with diethylether. The aqueous layer was separated and then basified with 30% NaOH solution. The product was then extracted twice with CH2C12/ washed once with brine, dried (Na2S04) · filtered and solvent removed to give a crude brown liquid which was distilled (2-4 mmHg, 62-64°C) to give the title compound (8.0g, 58% yield). -78B. 8-chloro-ll-( 1,2,6-trimethy1-4-piperidinyl)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-1l-ol The chloride, 1,2,6-trimethyl-4-chloropiperidine, (4.2g, 26 mmol) was slowly dripped into a solution of dry THF (18 mL) containing Mg (633 mg, 26.3 mm). The Grignard reagent was then formed after heating for 6 hours at 70°C.
To a cooled (ice-bath), stirred solution of 8chloro-5,6-dihydro-llH.-benzo [5,6] cyclohepta [1,2-b] pyr idinll-one (6.3g, 26 mmol) in THF (50 mL) was added the above Grignard reagent. The reaction was allowed to stir for 1 hr. at this temperature and then quenched with NH4ci solution. The product was extracted 3X with EtOAc, washed once with brine, dried (Na2SO4), filtered and solvent removed to give a crude brown material which was chromatographed to give the title compound (5.1g, 53% yield) as a yellowish glass. -79C. 8-chloro-ll-(1-methyl-(Z)-2,6-dimethy1-4piper idylidene )-6,ll-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]pyridine A mixture of 8-chloro-ll-(l,2,6-trimethyl-4piperidinyl)-6,ll-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b] pyridin-ll-ol (5.0g, 14.1 mmol) in 85% H2SO4 (100 mL) was heated in an oil bath (60-65°C) for 3 hours. The reaction was cooled and diluted with water followed by basification with 25% aq. NaOH solution. The crude product was extracted with CH2C12Z washed with brine, dried (Na2SO4), filtered and solvent removed. Purification and separation of the E and Z isomers via chromatography (2% +5% MeOH saturated with NH3 in CH2CI2) gave the title compound (300 mg, 6%).
D. 8-chloro-ll-(l-cyano-(Z)-2,6-dimethyl-4-piperidylidene)6, ll-dihydro-5H-benzo[5,6]cyclohepta [1,2-b]pyridine A solution of 300 mg (0.85 mmol) of 8-chloro-ll(l-methyl-(Z)-2,6-dimethyl-4-piperidylidene)-6,ll-dihydro5_H_-benzo [5,6] cyclohepta [1,2-b]pyridine in benzene (4.5 mL) was slowly dripped into a stirred solution of BrCN (133 mg, -801.2 mmol) in benzene (4.5 mL) at room temperature. This was allowed to stir for 2½ hr under argon. The reaction mixture was suspended between water and EtOAc. The EtOAc layer was washed with brine and dried (NaSO^). After filtration the solvent was removed and the crude material was chromatographed (3% MeOH in CH2Cl2) to give the title compound (251 mg, 81% yield).
E. 8-chloro-ll-((Z)-2,6-dimethyl-4-piperidylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine H A mixture of 8-chloro-ll-(1-cyano-(Z)-2,6dimethyl-4-piperidylidene) -6, ll-dihydro-5Ilbenzo[5,6]cyclohepta[l,2-b]pyridine (200 mg, 0.55 mmol) in 80% HCI (20 mL) was allowed to reflux for 7 hours. The mixture was cooled and then basified with 25% NaOH. The product was extracted 2X with CH2C12/ separated, washed once with brine, dried (NaSO4), filtered and solvent removed to give the title compound (174 mg, 93% yield) as a white glass.
F. By following a similar set of procedures in steps D & E above 8-chloro-ll-(1-methyl-(E)-2,6-dimethyl-4piper idylidene) - 6, ll-dihydro-5_H-benzo [ 5,6] cyclohepta [1,2b]pyridine was converted to 8-chloro-ll-((E)-2,6-dimethyl-4piper idylidene-6, ll-dihydro-5jl-benzo[ 5,6] cyclohepta [ 1,2b]pyr idine. -81PREPARATIVE EXAMPLE 7 8-Chloro-ll-(4-piperidylidene)-6,ll-dihydro-3-methy15H-benzo15,6]cyclohepta11,2-b]pyr idine A. 3,5-DIMETHYLPYRIDINIUM N-OXIDE A solution of 285 mL (1.31 mol) of 35% peracetic acid was slowly added to a stirred solution of 149g (1.39 mol) of 3,5-dimethylpyridine during which the temperature rose to 85°C and was maintained at this temperature during addition. After the temperature of the mixture dropped to about 35eC the reaction was stored at 5°C overnight.
After partial removal of 185 ml of acetic acid via distillation under vacuum, the reaction was washed with NaHSO^ solution and then neutralized with 10% NaOH solution to pH of about 7. The product was extracted with CH2CI2 to give the title compound as a white solid (yield 142 g, 83%). Β. l-METHOXY-3,5-DIMETHYLPYRIDINIUM METHYL SULFATE Dimethylsulfate (42.Og, 0.33 mol) was slowly added to a mechanically stirred solids of 41.Og (0.33 mol) of 3,5dimethylpyridinium N-oxide. The mixture was then heated on steam bath for 1 hr. Then vacuum was applied while cooling to give a brownish solid of the title compound in quantitative yield. -82C. 2-CYANO-3, 5-DIMETHYLPYRIDINE To a cooled (0°C) solution of 49.Og (.999 mol, 3.0 eq.) of sodium cyanide in 135 mL of water (air free) was dripped in 83.Og (0.33 mol) of l-methoxy-3,5-dimethyl pyridinium methyl sulfate in 100 mL water (air free) in 1¾ hr., keeping temperature below 3°C. The reaction mixture was stored at about 3°C overnight. The mixture was filtered and washed with water to give 40g of the title compound (yield 91%). An analytical sample was recrystallized from isopropyl ether and pentane (4:1) to give a m.p. 61-62°C.
D. N-(1,1-dimethylethyl)-3,5-dimethyl-2-pyridine carboxamide CN o To a stirred solution of 20.3g (0.153 mol) of 2cyano-3,5-dimethylpyridine in 100 mL of acetic acid was added 20 mL of cone, sulfuric acid within 10 minutes (temp, rose to 35°C), followed by 20 mL of t-butanol over an additional 15 minutes. The solution was warmed at 75°C for 30 minutes after which it was cooled to room temperature and basified with 25% NaOH. The product was extracted 3X with EtOAc (600 mL), which was combined and washed lx with brine, dried (Na2SO4), filtered and concentrated in vacuo to give the title compound (31.26g, 98%) as a yellowish oil. -83E. 8-Chloro-ll-(4-piperidylidene)-6,ll-dihydro-3methyl-5H-benzo[5,6]cyclohepta[1,2-b]pyridine By substituting in step IB above N-(l,ldimethylethyl)-3,5-dimethyl-2-pyridine carboxamide for N(lr1-dimethylethyl)-3-methyl-2-pyridine carboxamide and employing basically the same methods as steps B through G, one obtains 8-chloro-ll-(4-piperidylidene)-6,ll-dihydro-3methyl-5H7benzo[5,6]cyclohepta[1,2-b]pyridine. Reaction times are determined by TLC or HPLC.
PREPARATIVE EXAMPLE 8 11-(4-Piperidyl)-6,ll-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]pyr idine A. (l-Methyl-4-piperidinyl)[3-(2-phenylethyl)-2pyridinyl]methanol To a mixture of 5.0g (16.2 mmole) of (l-methyl-4piperidinyl)[3-(2-phenylethyl)-2-pyridinyl]methanone (which can be prepared in the same manner as described in Preparative Example 1, Steps A-D) in 70 mL of methanol was added portionwise 0.8g (21.1 mmole) of sodium borohydride. The next day the solution was concentrated in vacuo to give a slurry which was dissolved in water and extracted with CHCl^. The combined organic portions were dried over MgSO^, filtered, and concentrated in vacuo to provide a liquid which was distilled (bp 190-195°C 1 mm Hg) to give 4.4 gms (87%) of the title compound as a viscous oil. -84B. 11-(l-Methyl-4-piperidyl)-6,ll-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]pyridine A mixture of 3.5 gm (11.3 mmole) of 4-(1-methylpiperidyl)-2-[3-(2-phenylethyl)pyridyl]methanol and 200g of polyphosphoric acid was heated between 160-170°C for 13 hours. The mixture was cooled to room temperature, poured into water, basified with aqueous NaOH and extracted with ether. The combined organic portions were concentrated in vacuo and the product recrystallized from isopropyl ethyl to give the title compound as a white solid: mp 111-114°C.
C. In a similar manner to that described in Example 1, Steps F-G, 11- (l-methyl-4-piperidyl)-6,ll-dihydro-5iibenzo[5,6]cyclohepta[l,2-b]pyridine can be converted to 11(4-piperidyl)-6,ll-dihydro-5H-benzo[5,6]cyclohepta[1,2-b] pyr idine. -85EXAMPLE 1 8-CHLORO-11-(1-METHOXYACETYL-4-PIPERIDYLIDENE) -6,11DIHYDRO-5H-BENZO(5,61CYCLOHEPTA(1,2-b]PYRIDINE Dissolve the title compound of Preparatory Example 1G above, 8-chloro-ll-(4-piperidylidene)-6,ll-dihydro-5Hbenzo[5,6]cycloheptall,2-b]pyridine (3.00 gm, 9.7 mmol) and l. 2 mL (14.8 mmol) of pyridine in dry methylene chloride (20 mL) at 0eC. under an argon atmosphere. Add methoxyacetyl chloride (1.1 mL, 12.0 mmol) dropwise, and slowly warm to room temperature. After 1.5 hours take up the mixture in methylene chloride and wash with brine. Dry over Na2SO4, filter, and concentrate in vacuo to give a residue and purify via flash chromatography. Triturate the product with pentane and recrystallize from ethyl acetate/pentane to give the title compound as a white solid. (1.89 g, Yield 66%, m. p. 104-106°C.).
EXAMPLE 2 OR 9-SUBSTITUTED-ll-(1-SUBSTITUTED-4-PIPERIDYLIDENE)6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA 11,2-b]PYRIDINE COMPOUNDS By substituting the acid halide and amine listed in the first and second columns, respectively, of Table IV below for the methoxyacetyl chloride and compound of Preparatory Example 1G, respectively in the process described in Example 1, above the product compounds listed -86in the third column of Table IV were prepared. Workup times were determined by monitoring the reaction by TLC. Reaction times and temperatures vary slightly. In some instances purification of the product by chromatography was not necessary. -87TABLE IV Amine Acid Halide (R2 and R4 same as in Amine) C100-R, R= R3_R4 R= 2= Product Melting Point °C -Cl -Cl -C(CH3)3 -€H2C(CH3)3 -Cl -Cl -H -C6H5 O -H -CH3 O -H -C(CH3)3 0 -H -CH2C(CH3)3 0 Conments glassy solid -Cl -Cl -Cl 155-157°^ 158-160°Cb 137-139°Cb 178-180°Cb -H -CO2C2H5 O 126-128°<5 136-138°C -88TABLE IV (Cont'd) Amine Product (R3 and R4 same Product Acid Halide as in Amine) Melting Point Comments C1C0-R, R3 R4 R= 2= °C -CH2CH2CH3 -Cl -H -CH2CH2CH3 0 119-122ec4 -c2h5 -Cl -H ^2H5 0 128-130°^ -ch2oc2h5 -Cl -H 0 107-109°C triturated from isopropyl ether after flash chromatog raphy -CH(CH3)OCH3 -Cl -H -CH(CH3)OCH3 0 128-130°^0 -C(O)CH3 -Cl -H -C(O)CH3 0 150-152°CC -CH2OCH3 -H -Cl -ch2och3 0 104-107°^ -ch2och3 -ch3 -H —ΟΗ2θΟΗ3 ο — glassy solid -ch2och3 -H -H —CH26CH3 0 87-89°C -020¾ -F -H -CH2OCH3 0 114-116β<5 -89TABLE IV (Cont'd) Amine Product (R3 and R4 same as in Amine) Product Melting Point Comments Acid Halide C1CO-R, R3 R4 R= Zf= °C -F -H -CH2CH2CH3 0 123-125°<5 -CH2OCH3 -H -F -ch2och3 0 113-115°Cc ^3 -Η -F -ch3 0 — -ch3 -F -H -ch3 0 — -ch2och3 -F -F -ch2och3 0 151-152°<5 -C(O)CH3 -Cl -H -CH(0H)CH3e 0 — -c6h5 -Cl -H s 147-150°Cf —ch3 -H -ch3 0 — -®3 -Cl -Cl —ch3 0 177-179°C -ch3 -Cl -H -ch3 s 153-155°C -ch3 -0CH3 -H -ch3 0 —— glassy solid glassy solid glassy solid g glassy solid glassy solid -90TABLE IV (Cont'd) Amine Product Acid Halide (R3 and R4 same as in Amine) Product Melting Point C1CO-R, R= R3 R4 R= z= °C -ch3 -H -Cl -ch3 0 — —ch3 -F -F —ch3 0 188-139°C -ch3 -H -H -ch3 0 155-156°C -H -H 0 207-208°C Cl Cl -H -H O 0 157-158°C -H -H och3 -0-°°¾ 0 138-141 ®C ch3 Br H ch3 0 165-166 ch3 X ch3 0 160-162 -CH2CH=CH2 Cl H —ch2ch=ch2 0 157-158 Comments glassy solid -91Table IV (Cont'd) Amine Product Acid Halide (r3 and R4 same as in Amine) Product Melting Point Comments C1CO-R, R= _r£ R= Z= °C C(CH3)2OCH3 Cl H C(CH3)2OCH3 0 147-149 ch3 glass following oxidation with PDC in CH2C12 -92Table IV (Cont'd) Amine Product (R3 and R4 same as in Amine) Acid Halide Product Melting Point Conroe nt s °C 177-179°C glass a Recrystallized from acetone and pentane. b Recrystallized from ethylacetate and isopropylether. c Recrystallized from ethylacetate and pentane.
Recrystallized from isopropyl ether, θ Following reduction with NaBH^ in methanol.
Recrystallized with ethylacetate and diethylether.
The Z=0 compound produced is converted to the Z=S compound by a conventional sulfuration reaction employing Lawesson’s reagent. -93EXAMPLE 3 8-CHLORO-ll-(1-ACETYL-4-PIPERIDYLIDENE)-6 ,11-DIHYDRO-5HBENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE An alternate method of making the title compound is to dissolve the title compound of Preparative Example IG (3.02 g., 9.72 mmole) and pyridine (3.9 mL, 48.1 mmol) in dry methylene chloride (40 mL) at 0°C under an argon atmosphere and add dropwise acetic anhydride (4.5 mL, 47.7 mmole). Slowly warm the reaction mixture to room temperature. After 2 hours, take up the mixture in methylene chloride, wash with water (2x) and with brine. Dry the mixture over sodium sulfate, filter and concentrate in vacuo to give a product which is recrystallized from acetone and pentane to give the title compound as a white solid. (2.41 gm, Yield 70%, m.p. 155157°C.). -94EXAMPLE 4 OR 9-SUBSTITUTED-ll-(1-SUBSTITUTED-4-PIPERIDYLIDENE)6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA [1,2-b]PYRIDINE COMPOUNDS By substituting the acid anhydride and amine listed in the first and second columns, respectively, of •Table V below for the acetic anhydride and compound of Preparative Example 1G, respectively in the process described in Example 3 above, the product compounds listed in the third column of Table V were prepared. Workup times were determined by monitoring the reaction by TLC. Reaction times and temperatures vary slightly. In some instances purification of the product by chromatography was not necessary. -95Acid Anhydride TABLE V as in Amine) Melting Point Z= Comments O(COR)? R= R= °C CH, CH, CH, r3=C1 R^H R=CHo rW R-CH, X=N R3=C1 R^H R=CHq r5=r°=ch3 X=N R3=R4=H R=CHq R5=R6=H X=CH 2=0 glass 2=0 glass 2=0 glass 142-144°C no pyridine was employed in alkylation -96EXAMPLE 5 8-chloro-ll-(l-acetyl-(Z)-2,6-dimethy1-4piperidylidene)-6,ll-dihydro-5H-ben2o[5,6] cyclohepta[1,2-b]pyridine To a solution of 8-chloro-ll-(l-acetyl-(Z)-2,6dimethy1-4-piperidylidene )-6, ll-dihydro-5j£-benzo [5,6] cyclohepta[1,2-b]pyridine (50 mg, 0.147 mmol) and N,Ndimethylaminopyridine (24 mg, 0.19 mmol) in dry CH2CI2 (2.6 mL) was added acetic anhydride (60 μΐ, 0.63 mmol). The reaction was stirred for 16 hours. The reaction was quenched with water and then diluted Na2CO3 solution.
The product was extracted with CH2Cl2 and washed with brine, dried (Na2SO^), filtered and solvent removed to give a crude which was isolated from preparative TLC plates (eluted with 5% MeOH in CHC13) to give the title compound (42 mg, 75% yield).
By a similar procedure 8-chloro-ll-(1-acetyl(E )-2,6-dimethy1-4-piperidylidene)-6, ll-dihydro-SjL-benzo[5,6]cyclohepta[1,2-b]pyridine was prepared. -97EXAMPLE 6 8-CHLORO-ll- [ 1- (ETHOXYCARBONYLMETHYL) -4-PIPERIDYLIDENE] 6 , 11-DIHYDRO-5H-BENZO [ 5,6] CYCLOHEPTA [ 1,2-b] PYRIDINE Dissolve the title compound of Preparative Example 1G (3.0 g., 9.7 mmol) in triethylamine (2.0 mL, 14.3 mmol), toluene (20 mL) and tetrahydrofuran (10 mL) at room temperature under an argon atmosphere. Add dropwise ethyl bromoacetate (1.30 mL, 11.7 mmol). After 1.5 hours, filter the mixture and concentrate in vacuo. Purify the residue via flash chromatography. Triturate the product with pentane and recrystallize from isopropylether to give the title compound as a white solid. (2.5 gms, Yield 65%, m.p. 80-82°C.).
EXAMPLE 7 Substitute the appropriate halide and amine from Table VI below into the process of Example 6 to yield the product compounds listed in column 3 of Table VI. The completion time for the reaction is determined by monitoring the reaction by TLC. The reaction time and temperature vary slightly. In some instances purification of the product by chromatography is not necessary. -98TABLE VI Halide cich2r R = Comments -O^OCHjQ^CH R3=C1, ί0=Η R3=C1, R^H, Z=H2 r=-ch2och2ch2ch glassy solid3 (CH3); R3=C1, R^H, R3=C1, r4=H, Z=H2 r=-ch2ch2ch-^^c (ch3) 3 OH glassy solidb Reaction utilizes KI and K2CO3 in toluene; Reflux 8 hours.
Obtained by reduction of the precursor ketone with NaBH4 in methanol. -99EXAMPLE 8 8-CHLORO-ll-[1-(t-BUTOXYCARBONYLAMINOACETYL)-4PIPERIDYLIDENE]-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE Dissolve N-t-butoxycarbonylglycine (1.84 g, .5 mmol), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (DEC) (2.80 g, 14.6 mmol), 1hydroxybenzotriazole hydrate (HOBT) (1.98 g, 14.7 mmol), in triethylamine (Et^N) (2.0 mL, 14.3 mmol) and dry methylene chloride (30 mL) at 0°C and under an argon atmosphere. Add dropwise a solution of the title compound from Preparative Example 1G (3.0 g., 9.7 mmol) in dry methylene chloride (15 mL). After 1.5 hours, take up the mixture in methylene chloride and wash with water and then with brine. Dry over sodium sulfate, filter and concentrate in vacuo to give an oil which is purified with flash chromatography (5% MeOH in CHC13). Recrystallize the purified product from ethyl acetate and pentane to give the title compound as a white solid. (4.15 gm, Yield 91%, m.p. 209-211’C). -100EXAMPLE 9 8-CHLORO-ll-(1-AMINOACETYL-4-PIPERIDYLIDENE)-6,11DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE Mix the title compound of Example 8 (2.50 g., .34 mmol) in a saturated hydrogen chloride solution in dioxan (35 mL), and stir at room temperature under an argon atmosphere overnight. Concentrate the mixture in vacuo and triturate the resultant gummy product with ethanol and diethylether to give the title compound as a white solid. (2.28 g., Yield 93%).
EXAMPLE 10 8-CHLORO-ll-(1-FORMYL-4-PIPERIDYLIDENE)-6,11-DIHYDRO5Η-ΒΕΝΖΟ(5,6]CYCLOHEPTA[1,2-b]PYRIDINE ci CHO -101Dissolve the title compound of Preparative Example IG (5.0 g., 16.1 mmol) in 100 mL of ethyl formate and reflux the mixture for 4 hours. Concentrate the mixture in vacuo and triturate the product with hexane to give the title compound as a white solid (2.2 gm, 40% yield, m.p. 147-149°C.).
EXAMPLE 11 8-CHLORO-ll-(1-METHYLAMINOCARBONYL-4-PIPERIDYLIDENE)6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE To a mixture of 2.03g (6.53 mmole) of 8-chloroll- (l-acetyl-4-piperidylidene) -6,ll-dihydro-5.Hbenzo[5,6]cyclohepta[l,2-b]pyridine and 1.0 mL of triethylamine in 30 mL of dry THF at -10°C and under a nitrogen atmosphere was added dropwise over 10 minutes 0.40 mL (6.78 mmole) of methylisocyanate. The mixture was slowly warmed to room temperature. After 4 hours it was poured in water and extracted 3x with CH2C12· The organic portions were combined, dried over MgSO4» filtered and concentrated in vacuo to afford a product which was recrystallized from CH2Cl2/ethyl acetate/hexanes to give 1.70g (71%) of the title compound as white crystals: m.p. 194.5-196°C. -102EXAMPLE 12 -Hydroxy-8-chloro-ll-(l-acetyl-4-piperidylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta [ 1,2-bI pyridine H To a mixture of 32.6 mg (0.10 mmole) of 5hydroxy-8-chloro-ll-(4-piperidylidene)-6, 11-dihydro-5jl·benzo [5,6]cyclohepta[1,2-b]pyridine and 9.7 yl (0.12 mmole) of pyridine in a solution of 2 mL of methanol and 1 mL of CH2CI2 at 0°C and under a nitrogen atmosphere was added 11.3 yl (0.12 mmole) of acetic anhydride. After 30 min. the mixture was poured into water which was subsequently adjusted to pH of about 9 with aqueous sodium hydroxide. The mixture was extracted 2x with CH2C12· The organic portions were combined, washed once with brine, dried over Na2SO4, filtered, and concentrated in vacuo to yield 31.2 mg (85%) of the title compound asa glass.
EXAMPLE 13 N-METHYL-8-CHLORO-ll-(1-ACETYL-4-PIPERIDYLIDENE)-6,11DIHYDRQ-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINIUM IODIDE "/Δ -103A mixture of 500 mg (1.42 mmole) of 8-chloroll- ( 1-acetyl-4-piperidylidene)-6, ll-dihydro-5ji_-benzo (5,6] cyclohepta [l,2-b]pyridine and 175 yl (2.81 mmole) of methyl iodide in 30 mL of toluene was heated at 100°C for about 19 hours. The reaction mixture was cooled to room temperature and the solvent decanted off. The remaining residue was recrystallized twice from CH2Cl2/isopropyl ether/hexanes to give 432 mg (61%) of the title compound as tan crystals: m.p. 245-247°C.
EXAMPLE 14 8-CHLORO-ll-(1-ACETYL-4-PIPERIDYLIDENE)-6,ll-DIHYDRO-SHBENZO [5,6]CYCLOHEPTA[1,2-b]PYRIDINE-N-OXIDE To a mixture of 711 mg (2.01 mmole) of 8chloro-ll-( l-acetyl-4-piperidylidene )-6, ll-dihydro-5j£benzo[5,6] cyclohepta[1,2-b]pyridine in 30 ml of dry CH2C12a*- -10°C and under a nitrogen atmosphere was added 246 mg (1.60 mmole) of m-chloroperoxybenzoic acid. After 95 min. the mixture was taken up in CH2C12 an<3 washed once with 10% aqueous sodium bisulfite and once with 10% aqueous sodium hydroxide. It was dried over magnesium sulfate, filtered, and concentrated in vacuo. The product was purified via flash chromatography (5+8% MeOH in CH2C12) and recrystallized from ethyl acetate/hexanes to give 175 mg (26%) of the title compound as a hemiethyl acetate solid: m.p. 90.5-93°C. -104In a similar manner 8,9-difluoro-ll-(1-acetyl4-piperidylidene)-6,ll-dihydro-5Kl·-benzo[5,6]cyclohepta [1,2-b]pyridine was converted to 8,9-difluoro-11(1acetyl-4-piperidylidene )-6, ll-dihydro-5j^-benzo [5,6] cyclohepta[1,2-b]pyridine-N-oxide.
EXAMPLE 15 8-CHLORO-ll-(l-ACETYL-4-PIPERAZINYL)-6,11-DIHYDRO-5H10 BENZQ[5,6]CYCLOHEPTA[1,2-b]PYRIDINE A mixture of 1.98g (7.50 mmole) of 8,11dichloro-6, ll-dihydro-5j£-benzo [5,6] cyclohepta [1,2— b]pyridine, 1.16g (9.05 mmole) of N-acetylpiperazine, and 2.0 mL of triethylamine in 20 mL of dry THF was refluxed under a nitrogen atmosphere for 16 hr. It was then poured into 5% aqueous sodium hydroxide and extracted three times with methylene chloride. The combined organic portions were dried over MgSO4, filtered and concentrated in vacuo to yield a product which was purified by flash chromatography (5% CH^OH in CHC13) to afford 1.71g (64%) of the title compound as a glass.
EXAMPLE 16 3Q By employing the appropriately substituted piperazine listed in Table VII in place of N-acetyl piperazine the desired products were prepared under basically the same conditions as described above. Workup time was determined by TLC. -105TABIE VII Product '^N | R Amine Product m.p. Ccnrnents B 0 /"Λ -n^jj-ch. 146-148°C CB3 a, NH \_y glass run at ambient temp, then reflux M glass run at ambient teitp., then reflux a 0 /-\ -N «Η· \_! 143-146°C employed large H. excess (11 equiv.) of piperazine with no Et3N run atcb ambient temp. glass piperazine was limiting reagent -106EXAMPLE 17 8-CHLORO-ll- [ 1-ACETYL-4-PIPERIDINYL] -11H-BENZO [5,6]CYCLOHEPTA[1,2-b]PYRIDINE A mixture of 1.17g (3.32 mmol) of 8-chloro-(lacetyl-4-piper idylidene)-6, ll-dihydro-5H-benzo(5,6] cyclohepta[1,2-b]pyridine in 4 mL of trifluoromethane sulfonic acid was heated between 180-200°C for 3 days under a nitrogen atmosphere. The mixture was cooled to room temperature, poured into 10% aqueous sodium hydroxide and extracted three times with CH2CI2. The organic portions were combined, dried over MgSO^, filtered, and concentrated in vacuo. The residue was purified via flash chromatography [5% MeOH in CH2CI2] to give 534 mg (46%) of the title compound as a glass.
The following are examples of pharmaceutical dosage forms which contain a compound of the invention.
As used therein, the term active compound is used to designate the compound 8-chloro-ll-(l-acetyl-4piper idylidene)- 6, ll-dihydro-5_H-benzo [ 5,6]cyclohepta[1,2-b]pyridine. The scope of the invention in its pharmaceutical composition aspect is not to be limited by the examples provided, since any other compound of structural formula I can be substituted into the pharmaceutical composition examples. -107Pharmaceutical Dosage Form Examples Example A Tablets No. Ingredient mg/tablet mg/tablet 1. Active Compound 100 500 2. Lactose USP 122 113 3. Corn Starch, Food Grade, as a 10% paste in Purified Water 30 40 4. Corn Starch, Food Grade 45 40 5. Magnesium Stearate 3 7 Total 300 700 Method of Manufacture Mix item nos. 1 and 2 in a suitable mixer for 10-15 minutes. Granulate the mixture with item no. 3. Mill the damp granules through a coarse screen (e.g., 1/4) if needed. Dry che damp granules. Screen the dried granules if needed and mix with item no. 4 and mix for 10-15 minutes. Add item no. 5 and mix for 1-3 minutes. Compress the mixture to appropriate size and weight on a suitable tablet machine. -108Example B Capsules No. Ingredient mg/capsule mg/capsule 1. Active Compound 100 500 2. Lactose USP 106 123 3. Corn Starch, Food Grade, 40 70 4. Magnesium Stearate NF 4 7 Total 250 700 Method of Manufacture Mix item nos. 1, 2 and 3 in a suitable blender for 10-15 minutes. Add item no. 4 and mix for 1-3 minutes. Fill the mixture into suitable two-piece hard gelatin capsules on a suitable encapsulating machine.
While the present invention has been described in connection with certain specific embodiments thereof, it will be evident to one of ordinary skill in the art that many alternatives, modifications and variations may be made. All such alternatives, modifications and variations are intended to be included within the spirit and scope of the invention.
Claims (16)
1. A compound having the structural formula I or a pharmaceutically acceptable salt or solvate thereof, wherein: one of a, b, c and d represents N or NR^ where R^ is 0“, -CH3 or -(CH2) n CO 2 H where n is 1 to 3, and the remaining a, b, c and d groups are CH, which remaining a, b, c and d groups optionally may be substituted with R 1 or R 2 ; R 1 and R 2 may be the same or different and each independently represents halo, -CF3, -OR 10 , -COR 10 , -SR 10 , -N(R 10 )2, -No2, -OC(O)R 10 , -CO2R 10 , -OCO^ 11 , alkynyl, alkenyl or alkyl, which alkyl or alkenyl group may be substituted with halo, -OR 10 or -CO 2 r 10 ; r3 and R^ may be the same or different and each independently represents H, any of the substituents of R 1 and R 2 , or R 2 and r4 together may represent a saturated or unsaturated C 5 -c 7 fused ring; r5, r6, r7 and R° each independently represent H, -CF3, alkyl or aryl, with all available substitutable carbon atoms of the carbocylic group being intended as possible points of attachment, which alkyl or aryl may be substituted with -OR 10 , -SR 10 , -N(R 10 ) 2 , -NO 2 f COR 10 , OCOR 10 , -110OCO 2 R 13 ·, CO2R 10 / OPO3R 10 , or one of R 5 , R 6 , R 7 and R 8 may be taken in combination with R as defined below to represent -(CH 2 ) r - where r is 1 to 4 which may be substituted with lower alkyl, lower alkoxy, -CF 3 or aryl; R 3 · 8 represents H, alkyl or aryl; R 11 represents alkyl or aryl; X represents N or C, which C may contain an optional double bond to carbon atom 11; the dotted line between carbon atoms 5 and 6 represents an optional double bond, such that when a double bond is present, A and B independently represent H, -R 3 · 8 , -OR 11 or -OC(O)r1 8 , and when no double bond is present between carbon atoms 5 and 6, A and B each independently represent H 2 , -(OR 3 - 8 ) 2 r alkyl and H, (alkyl) 2 r -H and -OCfOlR 38 , H and -OR 3 · 8 , =0, aryl and H, =NOR 18 or -O-(CH 2 )p-O- where p is 2, 3 or 4 and R 3-8 is as previously defined# z Z represents 0 or S such that (a) when Z is 0, R may be taken in combination with R 8 , R 8 , R 7 or R 8 as defined above, or represents H, aryl, alkyl, cycloalkyl - representing saturated carbocyclic rings branched or unbranched of from 3 to 20 carbon atoms, alkenyl# alkynyl or -D wherein -D represents heterocycloalkyl previously defined and W is O, S or NR 3 - 0 wherein R 10 is as defined above -Illsaid cycloalkyl, alkyl, alkenyl and alkynyl being optionally substituted with from 1-3 groups selected from halo, -CON(R 10 )2, aryl, -OR 12 , -SR 12 , -N(R 10 )2, -N(R 10 )CO2R 10 , -COR 12 , -NO2 or -D, wherein -D and R 1 ® are as defined above and R 1 ^ represents R 1 ®, -(CH2)mOR 1 ® or - (CH2)qCO 2 R 10 wherein R 1 ® is as previously defined, m is 1 to 4 and q is 0 to 4, said alkenyl and alkynyl R groups not containing -OH, -SH or -N(R 1 ®) 2 on a carbon containing a double or triple bond respectively; and (b) when Z represents S, R represents in addition to those R groups above, aryloxy or alkoxy; said alkyl - (including the alkyl portions of alkoxy, alkylamino and dialkylamino) - representing straight and branched carbon chains and contains from one to twenty carbon atoms, said alkenyl - representing straight and branched carbon chains having at least one carbon to carbon double bond and containing from 2 to 12 carbon atoms, said alkynyl - representing straight and branched carbon chains having at least one carbon to carbon triple bond and containing from 2 to 12 carbon atoms, and said aryl - (including the aryl portion of aryloxy) - representing a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring.
2. A compound as defined in claim 1 wherein Z is O or S.
3. A compound as defined in claim 1 or claim 2 wherein R represents alkyl, cycloalkyl, alkenyl, aryl or alkyl substituted with OR 12 , SR 12 , N(R 10 ) 2 or COR 12 . 4 *
4. A compound according to any of claims 1-3 above wherein Z is 0. -1125. wherein c 6. wherein > atom. 7. wherein I 8. wherein ϊ 9. wherein I 10. A compound according to any of claims 1-4 above represents N. A compound according to any of claims 1-
5. Above represents a single or double bonded carbon A compound according to any of claims 1-
6. Above 3 represents halo and R 4 represents hydrogen. A compound according to any of claims 1-
7. Above R°, R 7 and R® represent H. A compound according to any of claims 1-8 above and B represent H. A compound of claim 1 which is:
8. -Chloro-ll-(l-acetyl-4-piperidylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-ll-(l-methoxyacetyl-4-piperidylidene)6, ll-dihydro-SJI-benzo [ 5,6]cyclohepta[1,2b]Cyridine; 8-Chloro-ll-(1-propionyl-4-piper idylidene)6,ll-dihydro-5H-benzo[5,6]cyclohepta[1,2b]pyridine; 8- Fluoro-ll-(l-acetyl-4-piperidylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine;
9. - Fluoro-ll-(l-acetyl-4-piper idylidene)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Bromo-ll[l-acetyl-4-piper idylidene]-6,lldihydro-SH-benzo [5,6]cyclohepta[1,2-b]pyr idine; -1138,9-Difluoro-11-(l-acetyl-4-piper idylidene)6,ll-dihydro-5H-benzo[5,6]cyclohepta[1,2b]pyridine; 8-Chloro-ll-(l-acetyl-4-piperidinyl)-6,lldi hydro-511-benzo [5,6] cyclohepta (1,2-b] pyridine N-oxide; 3,8-Dichloro-ll-(l-acetyl-4-piperidinyl)-6,11dihydro-5jH-benzo [5,6] cyclohepta [ 1,2-b] pyr idine;
10. 11-(l-Acetyl-4-piper idyl)-6,ll-dihydro-5Hbenzo[5,6]cyclohepta[1,2-b]pyridine; or 8-Chloro-ll-(1-acetyl-4-piperazinyl)-6,11dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine. 11. A pharmaceutical composition comprising a compound as defined in any one of claims 1-10 above in combination with a pharmaceutically acceptable carrier.
11. 12. A method for making a pharmaceutical composition comprising mixing a compound of formula I as defined in any one of claims 1-10 above with a pharmaceutically acceptable carrier.
12. 13. A process for producing a compound having structural formula I as defined in claim 1 characterized by: -114a) reacting a compound of formula II with a compound of formula III, where L represents a suitable leaving group 2Γ Z R—C—L -> I III b) direct conversion of an N-alkyl compound of formula V with a compound of formula III A B Aa -11514. A compound of the formula XII A z R U xzr wherein the substituents have the same definition as in formula I of claim 1.
13. 15. The use of a compound of formula I as claimed in claims 1- 10 for the preparation of a pharmaceutical composition for antiinflammatory and/or anti-allergy application.
14. 16. A process for producing a compound of structural formula I as defined in Claim 1, substantially as hereinbefore described by way of Example.
15. 17. A compound of structural formula I as defined in Claim 1, whenever produced by a process as claimed in Claim 13 or Claim
16. -
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/925,342 US4826853A (en) | 1986-10-31 | 1986-10-31 | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE872913L IE872913L (en) | 1988-04-30 |
| IE65174B1 true IE65174B1 (en) | 1995-10-04 |
Family
ID=25451584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE291387A IE65174B1 (en) | 1986-10-31 | 1987-10-29 | BenzoÚ5,6¾Cycloheptapyridines Compositions and Methods of Use |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US4826853A (en) |
| EP (3) | EP0270818B1 (en) |
| JP (1) | JPH0678316B2 (en) |
| KR (1) | KR930002489B1 (en) |
| AT (1) | ATE116310T1 (en) |
| AU (1) | AU604285B2 (en) |
| CA (2) | CA1305147C (en) |
| CS (1) | CS414391A3 (en) |
| DE (1) | DE3750929T2 (en) |
| DK (1) | DK73193D0 (en) |
| ES (1) | ES2068179T3 (en) |
| FI (1) | FI96768C (en) |
| HK (1) | HK186396A (en) |
| IE (1) | IE65174B1 (en) |
| IL (1) | IL84310A0 (en) |
| MY (1) | MY102986A (en) |
| NZ (1) | NZ222347A (en) |
| OA (1) | OA09546A (en) |
| PH (1) | PH26184A (en) |
| SG (1) | SG44597A1 (en) |
| WO (1) | WO1988003138A1 (en) |
| ZA (1) | ZA878128B (en) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3007193A (en) * | 1959-01-12 | 1961-11-07 | Nat Glass Company Inc | Adjustable hinge |
| US4804666A (en) * | 1985-08-14 | 1989-02-14 | Schering Corporation | Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines |
| US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| US5665726A (en) * | 1986-10-31 | 1997-09-09 | Schering Corporation | Benzo[5,6]cycloheptapyridines, compositions and methods of use |
| US5438062A (en) * | 1986-10-31 | 1995-08-01 | Schering Corporation | Benzo(5,6)cycloheptapyridines, compositions and methods of use |
| ES2091195T3 (en) * | 1988-04-28 | 1996-11-01 | Schering Corp | CONDENSED POLYCLIC COMPOUNDS, COMPOSITIONS, PREPARATION METHODS AND THEIR USE AS PAF ANTAGONIST, ANTIHISTAMINIC AND / OR ANTI-INFLAMMATORY AGENTS. |
| NZ228888A (en) * | 1988-04-28 | 1991-12-23 | Schering Corp | Derivatives of piperidine, piperidylidene and piperazine and pharmaceutical compositions |
| US4863931A (en) * | 1988-09-15 | 1989-09-05 | Schering Corporation | Antihistaminic fluoro substituted benzocycloheptapyridines |
| ES2012297A6 (en) * | 1989-04-10 | 1990-03-01 | Espnola De Especialidades Farm | Dichloro-substituted imidazole derivatives as antifungal agents. |
| US5095022A (en) * | 1989-07-04 | 1992-03-10 | Hokuriku Pharmaceutical Co., Ltd. | Piperidine derivatives and pharmaceutical compositions comprising the same |
| IL98572A (en) * | 1990-06-22 | 1995-07-31 | Schering Corp | Bis-benzo or benzopyrido cyclohepta piperidene, piperidylidene and piperazine compositions an methods of use |
| DK0553191T3 (en) * | 1990-10-10 | 1995-08-07 | Schering Corp | Pyridine and pyridine N-oxide derivatives of diarylmethylpiperidines or piperazines, preparations and uses thereof |
| US5416087A (en) * | 1990-10-10 | 1995-05-16 | Wong; Jesse K. | Bis-benzo, cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use |
| JPH089616B2 (en) * | 1990-10-10 | 1996-01-31 | シェリング・コーポレーション | Substituted imidazobenzazepines and imidazopyridazepines |
| KR920014799A (en) * | 1991-01-18 | 1992-08-25 | 나오가따 다이도 | Novel benzo [5,6] cyclohepta [1,2-b] pyridine derivatives and anti-allergic agents containing them |
| EP0515158A1 (en) * | 1991-05-23 | 1992-11-25 | Schering Corporation | Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use |
| WO1993002081A1 (en) * | 1991-07-23 | 1993-02-04 | Schering Corporation | Novel benzopyrido piperylidene compounds, compositions, methods of manufacture and methods of use |
| JP2974529B2 (en) * | 1992-02-20 | 1999-11-10 | 北陸製薬株式会社 | Amphoteric tricyclic compounds |
| ES2089815T3 (en) * | 1992-03-27 | 1996-10-01 | Schering Corp | DERIVATIVES OF BIS-ARIL-CARBINOL WITHOUT BRIDGE LINKS, COMPOSITIONS AND METHODS OF USE. |
| EP0642514B1 (en) * | 1992-03-27 | 1997-05-21 | Schering Corporation | Bridged bis-aryl carbinol derivatives, compositions and methods of use |
| AU4244593A (en) * | 1992-05-19 | 1993-12-13 | Schering Corporation | Pentacyclic antihistamines |
| ES2042421B1 (en) * | 1992-05-22 | 1994-08-01 | Uriach & Cia Sa J | PROCEDURE FOR OBTAINING 8-CHLORINE-11- * 1 - * (5-METHYL-3-PIRIDIL) METHYL * -4-PIPERIDILIDEN * -6,11-DIHYDRO-5H-BENZO * 5,6 * CYCLOHEPTA * 1 , 2-B * PIRIDINE. |
| PT708776E (en) * | 1993-07-13 | 2001-06-29 | Janssen Pharmaceutica Nv | ANTI-ALLERGIC IMIDAZOAZEPINS |
| US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| IL111235A (en) * | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Pharmaceutical compositions for inhibition of g-protein function and for treatment of proliferative diseases containing tricyclic compounds some such compounds and process for preparing part of them |
| US5721236A (en) * | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US5661152A (en) * | 1993-10-15 | 1997-08-26 | Schering Corporation | Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US6075025A (en) * | 1993-10-15 | 2000-06-13 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| DK0723538T3 (en) * | 1993-10-15 | 2002-03-18 | Schering Corp | Tricyclic carbamate compounds useful for inhibition of G protein function and for the treatment of proliferative diseases |
| US6365588B1 (en) | 1993-10-15 | 2002-04-02 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| ES2087818B1 (en) * | 1993-11-24 | 1997-03-16 | Uriach & Cia Sa J | 8-CHLORINE-11- (1 - ((5-METHYL-3-PIRIDYL) METHYL) -4-PIPERIDYLIDEN) -6,11-DIHYDRO-5H-BENZO- (5,6) CYCLOHEPTAL (1,2-B) PIRIDINE, SMOKING. |
| US5574173A (en) * | 1993-12-06 | 1996-11-12 | Schering Corporation | Tricyclic derivatives, compositions and methods of use |
| US5538986A (en) * | 1993-12-06 | 1996-07-23 | Schering Corporation | Tricyclic derivatives, compositions and methods of use |
| US5464840A (en) * | 1993-12-06 | 1995-11-07 | Schering Corporation | Tricyclic derivatives, compositions and methods of use |
| US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
| ES2080700B1 (en) * | 1994-07-27 | 1996-10-16 | Farmihispania S A | NEW PROCEDURE FOR THE OBTAINING OF LORATADINE. |
| ES2080699B1 (en) * | 1994-07-27 | 1996-10-16 | Farmahispania S A | NEW DERIVATIVES OF 2- (1-ETOXICARBONIL-4-PIPERIDILIDEN) METHYL) PIRIDINE AND A PROCEDURE FOR ITS OBTAINING. |
| ES2087026B1 (en) * | 1994-07-28 | 1997-03-16 | Uriach & Cia Sa J | NEW DERIVATIVE OF BENZO (5,6) CICLOHEPTA- (1.2-B) PIRIDINA. |
| US5461057A (en) * | 1994-09-08 | 1995-10-24 | Schering Corporation | Hydro-ethano-indeno-pyridines |
| US5700806A (en) * | 1995-03-24 | 1997-12-23 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US5684013A (en) * | 1995-03-24 | 1997-11-04 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| US5801175A (en) * | 1995-04-07 | 1998-09-01 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US5712280A (en) * | 1995-04-07 | 1998-01-27 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US5891872A (en) * | 1995-04-07 | 1999-04-06 | Schering Corporation | Tricyclic compounds |
| IL117798A (en) * | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases and pharmaceutical compositions comprising them |
| US5874442A (en) * | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| PE92098A1 (en) * | 1996-07-31 | 1998-12-31 | Schering Corp | TRICYCLIC N-CYANOIMINES USEFUL AS PROTEIN TRANSFERASE INHIBITORS FARNESILO |
| CN1047774C (en) * | 1996-09-10 | 1999-12-29 | 上海华联制药有限公司 | Prepn of azadiphenyl cycloheptyl ketenes |
| ATE281450T1 (en) * | 1996-09-13 | 2004-11-15 | Schering Corp | COMPOUNDS AS INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| US6040305A (en) * | 1996-09-13 | 2000-03-21 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| KR20000036111A (en) * | 1996-09-13 | 2000-06-26 | 둘락 노먼 씨. | Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
| CA2266014A1 (en) * | 1996-09-13 | 1998-03-19 | Schering Corporation | Tricyclic compounds useful for inhibition of farnesyl protein transferase |
| US5945429A (en) * | 1996-09-13 | 1999-08-31 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US6030982A (en) * | 1996-09-13 | 2000-02-29 | Schering Corporationm | Compounds useful for inhibition of farnesyl protein transferase |
| US5994364A (en) | 1996-09-13 | 1999-11-30 | Schering Corporation | Tricyclic antitumor farnesyl protein transferase inhibitors |
| US5861395A (en) * | 1996-09-13 | 1999-01-19 | Schering Corporation | Compounds useful for inhibition of farnesyl proteins transferase |
| US6071907A (en) * | 1996-09-13 | 2000-06-06 | Schering Corporation | Tricyclic compounds useful as FPT inhibitors |
| US5958890A (en) * | 1996-09-13 | 1999-09-28 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US5985879A (en) * | 1996-09-13 | 1999-11-16 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| KR20000036120A (en) * | 1996-09-13 | 2000-06-26 | 둘락 노먼 씨. | Tricyclic inhibitors of farnesyl protein transferase |
| US6130229A (en) * | 1996-10-09 | 2000-10-10 | Schering Corporation | Tricyclic compounds having activity as RAS-FPT inhibitors |
| US5925639A (en) * | 1997-06-17 | 1999-07-20 | Schering Corporation | Keto amide derivatives useful as farnesyl protein transferase inhibitors |
| TR200000114T2 (en) * | 1997-06-17 | 2000-08-21 | Schering Corporation | Benzo (5,6) cyclohepta (1,2-B) pyridine derivatives for the prevention of farnesyl protein transferase. |
| US6576639B1 (en) | 1997-06-17 | 2003-06-10 | Schering Corporation | Compounds for the inhibition of farnesyl protein transferase |
| US6051582A (en) * | 1997-06-17 | 2000-04-18 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| EP0991637B1 (en) * | 1997-06-17 | 2002-05-29 | Schering Corporation | Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives as farnesyl protein transferase inhibitors |
| JP2002504142A (en) * | 1997-06-17 | 2002-02-05 | シェーリング コーポレイション | Benzo (5,6) cyclohepta (1,2-B) pyridine derivatives useful for inhibiting farnesyl protein transferase |
| US6239140B1 (en) | 1997-06-17 | 2001-05-29 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US6211193B1 (en) | 1997-06-17 | 2001-04-03 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| ATE227281T1 (en) * | 1997-06-17 | 2002-11-15 | Schering Corp | COMPOUNDS AS FARNESYL-PROTEIN TRANSFERASE INHIBITORS |
| US6218401B1 (en) | 1997-06-17 | 2001-04-17 | Schering Corporation | Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase |
| US6228865B1 (en) | 1997-06-17 | 2001-05-08 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| DE69812945T2 (en) * | 1997-06-17 | 2004-03-11 | Schering Corp. | TRICYCLIC AMINOOXYAMID DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS |
| US6159984A (en) * | 1997-06-17 | 2000-12-12 | Schering Corporation | Farnesyl protein transferase inhibitors |
| US5945430A (en) * | 1997-06-17 | 1999-08-31 | Schering Corporation | Aminooxyamide tricyclic inhibitors of farnesyl-protein transferase |
| US6689789B2 (en) * | 1997-06-17 | 2004-02-10 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US5925648A (en) * | 1997-07-29 | 1999-07-20 | Schering Corporation | Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase |
| US6632455B2 (en) | 1997-12-22 | 2003-10-14 | Schering Corporation | Molecular dispersion composition with enhanced bioavailability |
| PE20001566A1 (en) | 1999-03-26 | 2001-02-05 | Ucb Sa | 1,4-SUBSTITUTED PIPERAZINES, 1,4-SUBSTITUTED PIPERIDINES AND 1-SUBSTITUTED 4-ALKYLIDENYL PIPERIDINES |
| US6686502B1 (en) | 1999-03-26 | 2004-02-03 | Ucb S.A. | Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
| US6455554B1 (en) | 1999-06-07 | 2002-09-24 | Targacept, Inc. | Oxopyridinyl pharmaceutical compositions and methods for use |
| US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| AU2002334383A1 (en) * | 2002-09-24 | 2004-04-19 | Morepen Laboratories Limited | An improved process for the production of desloratadine |
| WO2004108700A1 (en) * | 2003-03-12 | 2004-12-16 | Teva Gyogyszergyar Reszvenytarsasag | Processes for preparation of polymorphic forms of desloratadine |
| ATE524445T1 (en) | 2005-06-23 | 2011-09-15 | Merck Sharp & Dohme | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF TYROSINE KINASE MET |
| US20070036859A1 (en) * | 2005-08-11 | 2007-02-15 | Perry Ronald L | Sustained release antihistamine and decongestant composition |
| JP2009512706A (en) | 2005-10-21 | 2009-03-26 | メルク エンド カムパニー インコーポレーテッド | Tyrosine kinase inhibitor |
| TW200813021A (en) | 2006-07-10 | 2008-03-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
| US20080287481A1 (en) * | 2006-09-08 | 2008-11-20 | Mayur Devjibhai Khunt | Process for the preparation of desloratadine polymorph mixtures |
| CN103113348B (en) * | 2013-02-18 | 2015-03-25 | 扬子江药业集团江苏海慈生物药业有限公司 | Pseudo-polymorphic form of desloratadine citrate disodium and preparation method thereof |
| CN110818684B (en) * | 2019-10-08 | 2023-04-07 | 深圳市南山区人民医院 | Inhibitor Lo-SH for resisting staphylococcus aureus virulence and biofilm formation and application thereof |
| CN110845473B (en) * | 2019-10-08 | 2023-04-07 | 深圳市南山区人民医院 | Inhibitor Lo-ethyl acetate for resisting staphylococcus aureus virulence and biofilm formation and application thereof |
| CN110818685A (en) * | 2019-10-08 | 2020-02-21 | 深圳市南山区人民医院 | Inhibitor Lo-isohexyl for resisting staphylococcus aureus virulence and biofilm formation and application thereof |
| EP4053116A4 (en) * | 2019-10-31 | 2023-10-11 | JD Bioscience Inc. | Tricyclic compound and pharmaceutical use thereof |
| CN115385892A (en) * | 2021-10-28 | 2022-11-25 | 天津市昕晨投资发展有限公司 | Desloratadine derivative, preparation method and application thereof |
| CN115141229B (en) * | 2022-07-21 | 2023-12-12 | 华创合成制药股份有限公司 | Antihistamine compound and preparation method and application thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL132137C (en) * | 1963-04-24 | |||
| US3419565A (en) * | 1963-04-24 | 1968-12-31 | Schering Corp | Aza-dibenzocycloheptenes |
| US3409621A (en) * | 1966-04-01 | 1968-11-05 | Schering Corp | Piperazino-aza-dibenzo-[a, d]-cycloheptenes |
| US3717647A (en) * | 1971-04-09 | 1973-02-20 | Schering Corp | Alpha-nicotinoyl phenylacetonitriles |
| FI762546A (en) * | 1975-09-15 | 1977-03-16 | Sandoz Ag | |
| US4335036A (en) | 1980-05-30 | 1982-06-15 | E. I. Du Pont De Nemours And Company | Plasticized polyvinyl butyral employing propylene oxide oligomers |
| US4355036A (en) * | 1980-06-19 | 1982-10-19 | Schering Corporation | Tricyclic-substituted piperidine antihistamines |
| US4282233B1 (en) * | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
| JPS61501205A (en) * | 1984-02-15 | 1986-06-19 | シェリング・コ−ポレ−ション | 8↓-chloro↓-6,11↓-dihydro↓-11↓-(4↓-piperidylidene)↓-5H↓-benzo[5,6]cyclohepta[1,2-b]pyridine and its salts, compounds thereof and pharmaceutical compositions containing these compounds. |
| EP0208855B1 (en) * | 1985-05-13 | 1991-03-06 | Schering Corporation | process for preparing piperidylidene dihydrodibenzo(a,d)cycloheptenes and aza derivatives thereof, compounds obtained by such process and the use of such compounds for preparing useful pharmaceutical compositions |
| US4804666A (en) * | 1985-08-14 | 1989-02-14 | Schering Corporation | Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines |
-
1986
- 1986-10-31 US US06/925,342 patent/US4826853A/en not_active Expired - Fee Related
-
1987
- 1987-10-29 AU AU83362/87A patent/AU604285B2/en not_active Ceased
- 1987-10-29 EP EP87115890A patent/EP0270818B1/en not_active Expired - Lifetime
- 1987-10-29 SG SG1996003470A patent/SG44597A1/en unknown
- 1987-10-29 IE IE291387A patent/IE65174B1/en not_active IP Right Cessation
- 1987-10-29 AT AT87115890T patent/ATE116310T1/en not_active IP Right Cessation
- 1987-10-29 KR KR1019880700738A patent/KR930002489B1/en not_active IP Right Cessation
- 1987-10-29 ZA ZA878128A patent/ZA878128B/en unknown
- 1987-10-29 PH PH36002A patent/PH26184A/en unknown
- 1987-10-29 EP EP87908033A patent/EP0330673A1/en active Pending
- 1987-10-29 EP EP94108677A patent/EP0685476A1/en not_active Withdrawn
- 1987-10-29 DE DE3750929T patent/DE3750929T2/en not_active Expired - Fee Related
- 1987-10-29 WO PCT/US1987/002777 patent/WO1988003138A1/en active IP Right Grant
- 1987-10-29 MY MYPI87002990A patent/MY102986A/en unknown
- 1987-10-29 JP JP63500276A patent/JPH0678316B2/en not_active Expired - Lifetime
- 1987-10-29 NZ NZ222347A patent/NZ222347A/en unknown
- 1987-10-29 IL IL84310A patent/IL84310A0/en not_active IP Right Cessation
- 1987-10-29 ES ES87115890T patent/ES2068179T3/en not_active Expired - Lifetime
- 1987-10-30 CA CA000550729A patent/CA1305147C/en not_active Expired - Fee Related
-
1989
- 1989-04-17 FI FI891806A patent/FI96768C/en not_active IP Right Cessation
- 1989-04-28 OA OA59569A patent/OA09546A/en unknown
-
1991
- 1991-12-30 CS CS914143A patent/CS414391A3/en unknown
-
1992
- 1992-02-07 CA CA000616309A patent/CA1321589C/en not_active Expired - Fee Related
-
1993
- 1993-06-21 DK DK93731A patent/DK73193D0/en not_active Application Discontinuation
-
1996
- 1996-10-03 HK HK186396A patent/HK186396A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2068179T3 (en) | 1995-04-16 |
| CS414391A3 (en) | 1992-09-16 |
| NZ222347A (en) | 1990-03-27 |
| ZA878128B (en) | 1988-04-29 |
| FI96768C (en) | 1996-08-26 |
| FI96768B (en) | 1996-05-15 |
| AU604285B2 (en) | 1990-12-13 |
| FI891806A0 (en) | 1989-04-17 |
| PH26184A (en) | 1992-03-18 |
| FI891806A (en) | 1989-04-17 |
| DE3750929T2 (en) | 1995-06-01 |
| DK73193A (en) | 1993-06-21 |
| JPH02500910A (en) | 1990-03-29 |
| OA09546A (en) | 1993-01-31 |
| EP0330673A1 (en) | 1989-09-06 |
| CA1321589C (en) | 1993-08-24 |
| KR880701716A (en) | 1988-11-04 |
| EP0685476A1 (en) | 1995-12-06 |
| IE872913L (en) | 1988-04-30 |
| MY102986A (en) | 1993-03-31 |
| IL84310A0 (en) | 1988-03-31 |
| JPH0678316B2 (en) | 1994-10-05 |
| DK73193D0 (en) | 1993-06-21 |
| AU8336287A (en) | 1988-05-25 |
| HK186396A (en) | 1996-10-11 |
| DE3750929D1 (en) | 1995-02-09 |
| KR930002489B1 (en) | 1993-04-02 |
| WO1988003138A1 (en) | 1988-05-05 |
| EP0270818A1 (en) | 1988-06-15 |
| ATE116310T1 (en) | 1995-01-15 |
| EP0270818B1 (en) | 1994-12-28 |
| US4826853A (en) | 1989-05-02 |
| CA1305147C (en) | 1992-07-14 |
| SG44597A1 (en) | 1997-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0270818B1 (en) | Benzo(5,6)cycloheptapyridines, compositions and method of use | |
| AU646878B2 (en) | Bis-benzo or benzopyrido cyclo hepta piperidene, piperidylidene and piperazine compounds and compositions | |
| US5089496A (en) | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies | |
| EP0341860B1 (en) | Benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use | |
| US5104876A (en) | Benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use | |
| US5438062A (en) | Benzo(5,6)cycloheptapyridines, compositions and methods of use | |
| US5665726A (en) | Benzo[5,6]cycloheptapyridines, compositions and methods of use | |
| NO173062B (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE BENZO (5,6) CYCLOHEPTAPYRIDINES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |